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SIGNIFICANCE OF SPUTUM VOLUME PRODUCTION IN 
TUBERCULOSIS PATIENTS IN KAMPALA, UGANDA 
CASSANDRA MARIE PIERRE 
ABSTRACT 
Background: Traditionally, the concentration of mycobacteria in the sputum has been 
used as a marker of severity as well as a measure of treatment response in pulmonary 
tuberculosis (TB), however, because of its poor sensitivity for the prediction of TB 
treatment outcomes (particularly in HIV co-infected patients) more effective surrogate 
markers are needed. Sputum volume itself has not been previously studied as a 
potential determinant of treatment outcome. 
Objectives: To assess the association between sputum volume and clinical and 
radiographic markers of pulmonary TB as well as treatment outcomes among a sample 
of patients treated for pulmonary tuberculosis at the Mulago Hospital Uganda National 
Tuberculosis and Leprosy Programme (NTLP) Clinic in Kampala, Uganda. 
Methods and Findings: Patients admitted to NTLP between July 2003 to January 2007 
were enrolled into a prospective cohort study to assess treatment outcomes during and 
after a course of antituberculous therapy. From this cohort, a secondary analysis of 391 
study participants (with a mean follow-up t ime of 55 months) was conducted to assess 
the relationship between baseline sputum volume and TB treatment outcome. Of 296 
subjects with at least one spot sputum at baseline, a multivariable analysis revealed that 
having higher volume sputum (~ 3 ml) at baseline was significantly associated with the 
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presence of cavitary disease (odds ratio (OR) 2.06, 95% confidence interval {CI) 1.2-3.54) 
and male gender {OR 2.1, 95% Cl1.22-3.62). Among 196 participants with spot sputum 
specimens who had sufficient microbiologic or demographic data to make a 
determination regarding their TB treatment outcome, a multivariable logistic regression 
revealed that having higher volume sputum (~ 3 ml) at baseline (OR 5.76, 95% Cl 1.6-
28.56, p = 0.03), increased duration of pre-treatment TB symptoms(~ 12 weeks; OR 
8.07, 95% (11.69-38.59, p = 0.009) and receipt of post-secondary school education {OR 
21.03, 95% Cl 2.49-177.55, p = 0.005) had significant associations with an unsuccessful 
TB treatment outcome. 
Conclusions: Sputum volume produced at the time of pulmonary TB diagnosis is 
associated with gender and cavitary disease. Of interest, there is a statistically 
significant increased risk for unsuccessful TB treatment outcomes among those with 
higher baseline sputum spot volume(~ 3 ml) in comparison to those with lower sputum 
volume (<3 mL). 
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GLOSSARY 
Baseline period: The baseline period is defined as the time interval measured from the date of 
hospital admission up to 2 weeks after the date of admission. 
Drug resistant tuberculosis: Resistance to either 1st or 2nd -line antituberculous therapy at 
baseline. 
Karnofsky score/performance status: A subjective score (scaled between 0-100) assigned by 
physicians to classify an individual's ability to function independently. A score of 70 denotes 
ability to perform self-care yet inability to perform normal activity or active work; a score of :o; 70 
is noted to be ulow" for the purposes of this study. 
Tuberculosis infection: Defined as culture-positive Mycobacterium tuberculosis infection for this 
study. Other laboratory or clinical factors were not taken into account. 
Tuberculosis treatment outcome: Successful treatment is defined as cure (negative AFB sputum 
culture after 5 months of initiation oftherapy) or completion of therapy. Unsuccessful 
treatment is defined as treatment failure, relapse, death or default. 
Retreatment tuberculosis case: Study participant who has been previously treated for TB but 
subsequently determined to have active pulmonary TB .and started on antituberculous therapy 
during the study period . 
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Introduction 
Background 
Despite the establishment of global targets for case detection, the availability of effective and 
well-tolerated therapy and the widespread implementation of DOTS (Directly Observed 
Treatment Short-Course) TB remains an urgent global health issue inextricably bound to 
poverty. Of the 9.4 million incident cases and 1.7 million deaths attributed to TB in 2009, it is 
estimated that 98% of the TB-related deaths occurred in the developing world 1. The 
environmental and biologic determinants of tuberculosis which link it to poverty have been 
discussed at length2'3 and include, in part, barriers to disease detection and treatment follow-up 
in low-resource settings. 
In low-income and middle-income countries, direct sputum smear microscopy is the primary 
method of pulmonary tuberculosis detection and was previously used as a marker of treatment 
outcome that informed treatment decisions. The method is rapid, inexpensive and specific for 
Mycobacterium tuberculosis in regions with high seroprevalence. The main limitations of direct 
microscopy are its relatively low sensitivity, especially in individuals co-infected with HIV (who 
are more likely to have smear-negative TB}, and variable quality of test depending on 
practitioner experience. Therefore, low case-detection rates are recognized to be, in part, a 
consequence of reliance on direct microscopy in resource-poor settings. Furthermore, studies 
have shown that conversion to negative sputum smear at month two of treatment is an 
unreliable indicator of treatment outcome 4; these findings have led to the World Health 
Organization's (WHO) removal of the recommendation for sputum smear examination at this 
time point in the consideration of further treatment decisions 5 . 
The inadequacies of microscopy-based TB diagnosis and follow-up are emphasized in 
immunosuppressed populations, particularly in HIV-positive patients. Diagnosis ofTB in patients 
with advanced HIV infection (and consequent impaired cellular immunityL is complicated by an 
altered symptom spectrum with atypical radiographic findings and development of 
extrapulmonary and disseminated disease. Therefore, the productive cough necessary for the 
submission of a diagnostic sputum smear and culture may be absent and necessitate the use of 
procedures such as sputum induction or gastric aspiration. Smear-negative tuberculosis is 
disproportionately higher in HIV-infected individuals compared to those who are HIV-negative 
and is associated with poor treatment outcomes (including disease relapse, recurrence and 
deathL particularly in developing regions5-8. In regions with limited laboratory resources or high 
rates of smear-negative TB, the ideal marker for determination of TB treatment outcome would 
be clinically-based, inexpensive and applicable to HIV-infected and -uninfected patients. A low-
cost predictor of treatment failure would serve to prioritize patients that merit further testing or 
treatment intensification. 
Cohort studies of pulmonary TB treatment outcomes in developing countries have consistently 
identified a number of clinicat microbiologic and radiographic findings associated with 
unsuccessful treatment outcomes. Among them are mycobacterial burden (as evidenced by 
miliary or cavitary lung disease9-10, less days to sputum culture positivitl3'39 and higher initial 
sputum smear grade9-11L other radiographic abnormalities (lymphadenopathy, bilateral lung 
involvement1\ longer duration of TB illness prior to treatment9, male gender12-14, patient's 
geographic distance from treatment facility12, poor treatment adherence10' 12' 15, HIV infection12-
14 and cigarette smoking15-17. Furthermore, TB disease characteristics-such as antituberculous 
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drug resistance 10'15, retreatment TB10, treatment interruption9'16 and absence of sputum smear 
conversion at 2 months9-are noted to be risk factors for TB treatment failure, default, relapse 
or death . Among HIV-infected populations, subst ance use18, < 9 months of antituberculous 
treatment19-20 and low initial CD4 count20 are additiona l risk factors associated with unsuccessful 
treatment outcome in developing countries. 
In order to link these predictors of unsuccessful t reatment outcome to quantifiable surrogates 
of treatment failure, more recent research has evaluated for the presence of inexpensive and 
easily obtained biomarkers21. In addition to sputum microbiology (2 month sputum culture 
conversion, sputum smear grade or days to baseline sputum culture positivity), these 
biomarkers have included sputum TB-specific antigens and nonspecific immune 
activation/inflammatory markers (such as CRP or sputum interferon gamma)21. To date, sputum 
culture status after 2 months of therapy has been the marker with which the greatest 
experience was held, however as previously mentioned, this predictor has been noted to be a 
poor prognostic marker for treatment outcome in individual patients . 
Sputum volume as a marker of morbidity, mortality and effectiveness of therapy has been 
evaluated extensively in patient populations with underlying pulmonary disease such as cystic 
fibrosis and chronic obstructive pulmonary disease (COPD). In COPD, increased sputum 
production is typically associated with underlying inflammation and thus, increased disease 
activity. In the setting of pulmonary TB, it is unclear whether more extensive disease is 
associated with a corresponding increase in the quantity of sputum and the significance of 
sputum volume as a potential predictor oftreatment outcome has not yet been formally 
evaluated in the literature. We therefore propose a study that will evaluate the association of 
3 
sputum volume (from specimens collected at diagnosis) with clinical and radiographic severity 
and assess its significance as a potential predictor of pulmonary TB treatment outcomes among 
HIV-infected and -uninfected patients. 
Importance 
Tuberculosis is a leading cause of preventable deaths in developing countries. The ability to 
predict individuals who are at risk for treatment failure are of particular of importance in areas 
where treatment goals have not been met. Uganda, a country with a high prevalence ·of 
tuberculosis and a treatment cure rate among the lowest in Africa at 32%-well below the 
global goal of 85% of smear-positive cases-would benefit from the use of low-cost surrogate 
markers that could serve as a predictor ofTB treatment failure . 
Sputum volume has not previously been evaluated as an adjunctive biomarker to laboratory and 
radiographic findings in the determination ofTB severity and treatment response . Assessment 
of baseline sputum volume values may allow for discrimination between future treatment 
failure or success among patients with the diagnosis of pulmonary TB. 
Study Population and Sample 
Sub-Saharan Africa carries the overwhelming share of global HIV/AIDS and bears the 
disproportionate burden of HIV-Tb co-infection, as approximately 80% of HIV-TB cases occurring 
in Sub-Saharan Africa (WHO 2010). 
Uganda ranks 16th in the list of 22 high-burden TB countries in the world and the annual Tb case-
detection rate in Uganda, although steadily improving over the past decade, falls short of the 
WHO global target rate of 75% (noted to be 44% in 2009). The Uganda National Tuberculosis 
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and Leprosy Programme (NTLP) Chemotherapy Center at Mulago Hospital in Kampala, Uganda 
serves as the national TB referral center as well as a local treatment clinic. This study is a 
secondary analysis of data collected prospectively from adult patients (>18 years old) with either 
confirmed, probable or possible pulmonary TB who were admitted to NTLP between July 2003 
and January 2007. 
Eligible individuals were recruited upon admission and underwent a history and physical 
examination, baseline and repeat chest X-rays and at least one sputum specimen (for smear and 
culture) at baseline. In addition, individuals were offered HIV testing and aT-cell subset count 
was performed in HIV-seropositive patients. Patients were offered a standard TB treatment 
regimen (6 months for newly diagnosed Tb cases and 8 months for retreatment Tb cases) and 
monthly follow-up was instituted until the completion of treatment. Follow-up was thereafter 
conducted on a quarterly basis for the duration of the study period and all information was 
recorded in a centralized database. The initial study had three specific aims: 1.) to determine the 
prevalence of antituberculous drug resistance in patients treated at the NTLP clinic at Mulago 
Hospital, 2.) to determine the rate of (and risk fa ctors for) nosocomial transmission of drug 
resistant TB in Mulago Hospital and 3.) to develop an intervention to optimize the management 
of drug resistant TB. 
Approval for the original study was granted by the AIDS Research Sub-Committee of the Uganda 
National Council of Science and Technology and the Institutional Review Boards (IRB) at the 
University of Medicine and Dentistry of New Jersey and the London School of Hygiene and 
Tropical Medicine; approval for this study has been granted by the Boston University IRB. To 
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date, the studies published from this dataset have evaluated the efficacy of drug-resistant TB 
detection and treatment22-25. 
The present analytic data set consists of a subset of the original cohort selected on certain 
inclusion/exclusion criteria (see below). Based on these criteria, three hundred and ninety one 
subjects were selected for inclusion into the present study and were evaluated retrospectively. 
Inclusion/Exclusion Criteria 
Original Study 
Inclusion Criteria 
• ~ 18 years old 
• Confirmed, probable and possible TB cases 
Exclusion Criteria 
• Judged too ill to provide informed consent 
Current (Secondary) Analysis 
Inclusion Criteria 
• At least one spot or early morning sputum specimen collected during the first 2 weeks 
of hospital admission 
• Confirmed positive TB sputum culture from baseline period 
Exclusion Criteria 
• No sputum volume measurement provided for baseline sputum sample 
• Enrollment in Aim 1 only (i.e., no follow-up visit data available) 
6 
Objective/Hypothesis 
1. Evaluate the association between baseline sputum volume (measured in mL) and 
baseline clinico-radiologic features of pulmonary TB severity. (Objective 1) 
• Increased sputum volume at the time of TB diagnosis will be associated with clinical 
markers of increased TB severity (Hypothesis 1) 
2. Assess the association between baseline sputum volume and an established biomarker 
indicative of favorable treatment outcome (i.e. negative sputum AFB smear or culture at 
2 months of treatment). (Objective 2) 
• There will be no association between increased sputum volume and positive sputum 
AFB smear or culture positivity at 2 months of treatment. (Hypothesis 2) 
3. Determine the association between baseline sputum quantity and pulmonary TB 
treatment outcomes. (Objective 3) 
• Increased sputum volume at the time of TB diagnosis will be associated with 
unfavorable treatment outcomes (i.e. treatment failure, relapse, default or death) . 
(Hypothesis 3) 
Methods 
Treatment of Pulmonary TB 
All of the patients were treated with a standard 8 month anti-TB treatment regimen that 
included isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z) and streptomycin (S) for 
the initial phase of treatment (2 months), 1 month of R, H, E and Z and a mainte·nance phase of 
R, Hand E (5 months). 
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Participants received daily DOT during their hospitalization. After discharge, subjects were 
followed monthly for the duration of their 8-month TB treatment course, at month 9 and every 
4 months thereafter for the duration of the study. During these follow-up visits, two sputum 
specimens were collected for AFB smear microscopy and culture at five predetermined time 
points (months 1, 2, 5, 8 and 12). HIV-infected patients with a CD4+ cell count less than 200 
cells/ 111 were referred for antiretroviral (ARV) therapy according to the existing guidelines. 
Mycobacteriology 
Spot and early morning sputum specimens collected on admission (hereafter referred to as 
'baseline' specimens) and follow-up visits were evaluated for volume and gross appearance. The 
gross appearance of sputum specimens was classified into blood-stained sputum, mucoid, 
purulent or saliva . Sputum specimen volume measurement was assessed (by a dedicated 
laboratory technician) in milliliters and completed by comparison of a reference container 
gradation to the volume in a specimen container. Sputum samples were thereafter processed 
for decontamination and were used to prepare smears as well as 7H10 agar solid and liquid 
media culture. Sputum smears were examined microscopically for acid fast bacilli (AFB) by 
aura mine 0 fluorescent staining. Decontaminated sputum sediments were cultured in either 
BACTEC 460 (for samples processed prior to July 2006) or BACTEC MGIT 960 (for samples 
processed after July 2006); the number of days from sediment inoculation until positive culture 
was determined for baseline specimens. A diagnosis ofTB was confirmed if Mycobacterium 
tuberculosis was isolated in at least one baseline solid or liquid culture. Baseline M. tuberculosis 
isolates underwent drug susceptibility testing (DST) for S, R, H, E and Z using BACTEC 460 or 
MGIT 960. 
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Study Design 
Baseline sputum volume is the main independent variable of interest and was evaluated for 
association with clinical and epidemiologic characteristics at baseline (Objective 1L 2-month 
sputum culture positivity (Objective 2) and unsuccessful TB treatment outcome (Objective 3) . 
Sputum specimens collected throughout the study were labeled by collection method (i.e. spot 
or early morning [EM]) and study outcomes were analyzed separately according to spot or EM 
categorization. As these sputum collection methods were thought to likely result in specimens 
of different volumes, the purpose of this separation of analysis by sputum collection method 
was to evaluate whether there were detectable differences in the relationship between sputum 
collection and the defined study outcomes. As study participants were expected to submit (but 
were not always able to provide) at least 2 spot and one EM sputum sample during the baseline 
period, there was overlap between the individuals included in the spot and EM analysis sets for 
all 3 study outcomes. 
For the purpose of this study the sputum volume variable consisted of the mean of up to the 
first three spot or EM sputum volumes collected within the baseline period. First sputum 
measurement in the spot or EM category was not used as the outcome measure due to the wide 
within-subject variability. (Not all study subjects provided three samples during the baseline 
period; in these cases the first volume specimen or the average of the first two volumes was 
used as the subject's sputum volume.) Sputum volume means< 3ml were categorized as 'low' 
volume and mean volumes~ 3ml were categorized as 'high'. The rationale for choosing this 
cutoff is given below. 
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Of note, a separate analysis was performed for Objectives 2 and 3 on those subjects who had 
more than one baseline sputum specimen for the spot and EM groups (see Appendix B, Tables 
4-7). In this assessment (for which subjects who only submitted one sputum sample in the 
baseline period were excluded) we noted that there were no significant differences in the 
outcome of bivariate and multivariate analyses for either EM or spot groups in comparison to 
those performed on the group as a whole. 
Subjects were grouped by their highest pre-treatment smear grades (that is, ifthe AFB smears 
from one subject were inconsistent across submitted baseline sputum specimens, the most 
positive smear was chosen) . As the median value for time to detection of TB in liquid culture for 
the overall sample was noted to be 6 days, this value was used as the cutoff for the baseline 
days to sputum culture positivity variable . Previously discussed predictors of two-month sputum 
conversion and TB treatment outcome (including age, gender, HIV serostatus, smoking status, 
chest X-ray abnormalities and retreatment TB) were also evaluated for in relation to the 
outcome measure of interest for each of the objectives. 
Statistical Analysis 
Data were stored in Microsoft Office Access 2003 and were analyzed using the Statistical 
Analysis System (SAS) version 9.1. A two-sided significance level of 5% was used for all analyses. 
Frequencies were calculated to describe the demographic characteristics of the study 
population. Descriptive analyses were performed to characterize the study sample at the time of 
enrollment and were stratified by baseline volume status(< 3ml or~ 3ml) . Univariate analysis 
was performed with chi -square testing and continuous exposure variables were evaluated with 
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Student's T-test) for normally distributed variables) and Wilcoxon rank-sum test (for non-
normally distributed variables) . 
Logistic regression model-building to identify factors associated for Objectives 1 through 3 was 
performed in a step-wise fashion . Factors were considered for inclusion as risk variables or 
confounders in the multivariate analysis based on the magnitude of the odds ratio (OR) obtained 
in the univariate analyses; if OR was~ 2 or~ 0.5, then the variable would be included in the 
model-building process. For Objectives 2 and 3, baseline sputum volume was held as a stat ic 
independent variable (in relation to either 2 month sputum culture positivity or unsuccessful TB 
treatment outcome) and addit ional variables were subsequently added to the model. Order of 
entry into the multiva riable model was determined by performance in a univariate logistic 
regression when paired with the volume variable .The variables were then added to the 
multivariable model by descending order of magnitude of effect on the volume variable OR. 
Confounding was assessed in the multivariable model by comparing the OR of the volume 
variable in the preceding model to the OR obtained after the addition of a potential confounder. 
If the volume variable OR changed more than 10% by the addition of the potential confounder 
in question, it was retained in the model. For Objective 1, the variable with the greatest 
measure of effect (as described by the OR) was held as the static independent variable in the 
multivariable model; the order of entry and retention of additional variables to the model then 
proceeded as described above. Ninety-five percent confidence intervals (CI) were computed for 
each odds ratio. Model Akaike's Information Criterion (AIC) values and the Hosmer-Lemeshow 
test for goodness of fit were used to evaluate the goodness of model calibration. (-statistics 
were used to assess model discrimination. 
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In addition, stratification of dependent variables by HIV-serostatus (a potential confounder) was 
performed in the analysis of objectives 1 through 3. Stratification was performed for statistical 
purposes (to obtain estimates of precision for the HIV-infected and HIV-uninfected strata) and 
for clinical reasons (HIV-infected and -uninfected sub-populations were expected to have 
differences in type and magnitude of associations for risk predictors of TB treatment outcome). 
Results 
Determination of Sputum Volume Category 
Sputum volume was categorized as <3 ml (low volume category) or~ 3 ml (high volume 
category). This value was selected through visual and statistical evaluation of potential cut-off 
points on the approximately normal sputum volume distribution chart (see Appendix, Figure 1). 
Furthermore, setting the cut-point at 3 ml allowed for an evaluable data-set with which to 
assess study objectives. For example, in Objective 1, there were 203 participants with low 
sputum volume and 188 with high sputum volume at baseline. An ROC curve was not used for 
sputum volume cut off selection due to the absence of a defined endpoint (for example 
presence of TB disease or sputum positivity) in this pre-selected patient sample. 
Participant Characteristics 
Of 481 subjects admitted to the NTLP clinic between July 2003 and January 2007, 391 
participants had baseline and follow-up information as well as a positive TB sputum culture that 
was collected within the baseline period (i.e . within the first 2 weeks of admission); see Figure 1. 
Of these 391 participants, 296 had at least one spot sputum sample obtained during the 
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baseline period and 360 participants had at least one EM sputum obtained during this same 
time period . A total of 247 subjects submitted 3 or more baseline sputum samples . For 
Objective 2, there were 270 subjects with a spot sputum sample collected during the second 
month of antituberculous therapy (defined as a sputum specimen obtained during week 6 
through week 10 oftreatment) and 301 subjects with an EM sputum sample obtained during 
this period. For Objective 3, 196 participants we re noted to have at least one spot sputum 
sample obtained within the 51h to 81h month ofTB treatment and 221 participants were noted to 
have had at least one EM sputum sample collected within this same time period. (For Objective 
3, the latest sputum specimen available was used to determine treatment outcome.) 
General demographic, clinical and radiographic participant characteristics at baseline are noted 
in the Appendix, Table 1. Participants' mean age was 33.8 (range 18-75.2, S.D. 10.03); subjects 
included 249 males (63.7%) and 142 females (36.3%). 204 (52.3%) of the participants were HIV-
infected. The mean volume of baseline sputum specimens was 3.3 ml and 188 participants had 
a high sputum volume (48.1%) while 203 had a low sputum volume (51.9%). Female subjects in 
this study were 3.47 times as likely to be HIV infected as male participants (95% Cl 2.23-5.4, p 
<.0001; see Appendix Table 2). The baseline characteristics ofthe group were analyzed 
separately depending on the method of sputum collection and are discussed below (see Tables 
1-6). 
Of note, an evaluation of participants who were included in both the EM and spot groups (i.e. 
overlapping; n = 265) and those who were evaluated in EM or spot only (non-overlapping n = 
126) was performed to assess whether the two groups were similar in baseline demographics 
and clinicoradiographic presentation. Although there was no difference between sputum 
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volume category and demographic variables for the overlapping and non-overlapping 
participants, the non-overlapping subjects had higher sputum volume values (for both the 
continuous and categorical variables) and higher HIV seroprevalence. However, there were no 
differences between the non-overlapping EM and spot participants in regards to the baseline 
characteristics assessed for Objective 1. Furthermore, the association between higher volume 
category and male gender, cavitary disease and HIV infection persisted when analyzed 
separately in the non-overlapping EM, non-overlapping spot and overlapping groups. Therefore, 
we conclude that the two groups were essentially similar and did not remove the non-
overlapping participants from our subsequent analysis. 
Objective 1: Baseline participant characteristics according to sputum volume status 
Unstratified analysis 
For Objective 1, a cross-sectional analysis of baseline characteristics was conducted on the study 
participants. As previously documented, findings were separated into an analysis of participants 
who submitted at least one spot sputum sample and those who submitted at least one EM 
sputum sample in the baseline period. The volume variable for the subjects in these two groups 
is created from an average of the collection type-specific sputum volume obtained from an 
individual participant during the baseline period. 
In the spot group, subjects with higher volume of sputum were more likely to be male (OR= 
2.22, 95% (11.35-3.64, p = 0.002), be HIV-infected (OR= 1.78, 95% 01.12-2.83, p = 0.02) and to 
have cavitary disease on presentation (OR= 2.23, 95%01.38-4, p = 0.002) in the univariate 
analysis. When assessed in the multivariate analysis, only cavitary lesions (OR 2.06, 95% Cl1.2-
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3.54, p = 0.009) and male gender (OR 2.1, 95% Cl 1.22-3.62, p = 0.008) retained a significant 
association with increased baseline sputum volume (see Tables 1 and 3) . 
In the EM group, there were no statistically sign ificant associations between the participants' 
baseline characteristics and sputum category group for either the univariate or multivariate 
models (see Tables 3 and 4). 
Stratified ana lysis 
For the HIV-infected subgroup ofthe spot analysis (refer to Tables 7-9), higher sputum volume 
category was associated with male gender (OR 2.35; 95% Cl1.18-9.67, p = 0.02) and cavitary 
disease (OR 2.46; 95% Cl1.18-5.12) when compared to the low sputum volume category in the 
bivariate analysis . In the multivariate model, cavitary disease maintained a significant 
association with higher sputum volume (OR 2.45, 95% Cl1.18-5.12, p = 0.02). In the spot HIV-
uninfected subgroup and EM HIV-infected subgroups, however, there was no association 
between baseline characteristics and sputum volume in the . multivariate model. Bivariate 
analysis of the HIV-uninfected participants of the EM group revealed that the high sputum 
volume category was associated with male gender (OR 2.1, 95% Cl1.03-4.27, p = 0.04) as well as 
with a lower weight category (for> 50 kg; OR 0.52, 95% Cl 0.28-0.97, p = 0.04). In the 
multivariable analysis for this subgroup, male gender retained a significant association with 
higher sputum volume category (OR 2.1, 95% Cl1.03-4 .27, p = 0.04}. 
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Objective 2: Two-month sputum culture positivity 
Unstratified analysis 
Baseline study characteristics were again analyzed separately by baseline spot or EM sputum 
culture submission and were evaluated against two-month sputum culture positivity for 
Objective 2 (see Tables 19 and 21) . 
In the spot group univariate analysis, HIV-infected participants were noted to have 2.21 times 
the risk of having a positive two-month sputum culture when compared to those participants 
who were uninfected with HIV (95%(11.35-3.61, p = 0.002). In addition, those with any baseline 
drug resistance to 151 or 2nd line antituberculous agents (OR 2.09, 95%(11.08-4.04, p = 0.03), 
higher AFB sputum smear density at baseline (for increments of 1+, p <.0001), with cavitary 
disease (OR 2.54, 95% Cl1.47-4.39, p = 0.001) or history of current or prior cigarette smoking 
(OR 2, 95% Cl 1.18-3.36, p = 0.01) were more likely to have a positive sputum ex result at 2 
months of treatment . Having a baseline liquid sputum ex grow~ 6 days from the time of 
collection was protective against a positive two-month TB sputum ex (OR= 0.61, 95% Cl 0.37-
0.99, p = 0.05). There was no statistically significant relationship between increased sputum 
volume and two-month sputum culture positivity(~ 3ml; OR 1.24, 95% Cl 0.76-2.03, p = 0.45). 
In the logistic regression model for the spot group, the presence of cavitary disease at baseline 
(OR 2.71, 95% Cl1.5-4.88, p = 0.0009) and days to liquid sputum ex positivity at baseline (OR 
0.95, 95%CI 0.92-0.99, p = 0.01) retained a significant association with two-month sputum ex 
results when included in a model with volume category (OR 0.69, 95% Cl 0.38-1.25, p = 0.22). 
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In the EM group, those with a higher volume category at baseline were noted to have 1.76 times 
the risk of having a positive two-month TB sputum culture than those with a lower sputum 
culture at baseline (95%CI1.07-2.89, p = 0.03). In addition, HIV infection (OR 2.09, 95% Cl1.28-
3.4, p = 0.002), higher baseline AFB smear density (for measurements of 1+, p <.0001), presence 
of baseline cavitary disease (OR 3.2, 95% Cl1.65-6.19, p = 0.001) and history of current or prior 
smoking (OR 1.88, 95% Cl1.11-3.2, p = 0.03) were associated w/greater risk of a positive TB 
culture at 2 months of anti-tuberculous treatment . As in the spot group, a longer duration of 
time to a positive liquid sputum culture at baseline (time to growth;::: 6 days, OR 0.47, 95%CI 
0.35-0.94, p = 0.01) was associated with a decreased risk of having a positive TB sputum ex at 
two months of treatment. 
In the logistic model for the EM group including sputum volume, only baseline sputum smear 
AFB grade (for 1+ increment; OR 1.96, 95% Cl1.49-2.57, p <.0001) retained a significant 
association with two-month culture status (see Table 12). The volume category variable had no 
significant association with two-month culture status in the final model (OR 1.32, 95% Cl 0.77-
2.26, p 0.31). 
Stratified analysis 
For the HIV-infected participants of the spot group, participants with a longer self-perceived 
duration ofTB symptoms(~ 12 weeks) were 2.2 times as likely to have a positive two-month 
sputum culture as those with shorter duration (<12 weeks) of self-reported TB symptoms (95% 
01.04-5.05, p = 0.05) in the bivariate analysis. Although not clinically significant, there was a 
trend for those with a previous history of TB diagnosis and treatment (OR 2.28, 95% 01.02-
5.08, p = 0.051), prior history of smoking {OR 2.21, 95% 01.04-4.69, p = 0.06) and those with 
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cavitary disease at baseline (OR 2.2, 95% Cl 0.99-4.86, p = 0.07) to have a higher risk of a positive 
2 month sputum culture on treatment than those without these characteristics. In the 
multivariate model, prior smoking history was noted to be associated with (OR 2.76, 95% 01.1-
6.89, p = 0.03) two-month sputum culture positivity; sputum volume was not noted to have a 
significant association with two-month sputum culture positivity (OR 0.82, 95% Cl 0.35-1.9, p = 
0.63). 
In contrast, the HIV-uninfected participants in the spot group were noted to have a significantly 
increased risk of 2-month sputum culture ifthey possessed a higher sputum AFB smear density 
(for increments of 1 +; p = 0.0003) or a longer duration of TB symptoms at baseline (for~ 12 
weeks of symptoms; OR 3.82, 95% (11.78-8.23, p = 0.04). Longer duration ofTB symptoms at 
baseline retained significance with two-month sputum culture positivity (OR 4.02, 95% (11.82-
8.88, p = 0.04) when included in a multivariate analysis with sputum volume; higher sputum 
volume category itself was not significantly associated with two-month sputum culture positivity 
(OR 1.25, 95% Cl 0.56-2.81, p = 0.59). 
For the HIV-infected subjects in the EM group, days to sputum positivity in liquid culture (for> 6 
days; OR= 0.46, 95% Cl 0.23-0.94, p = 0.04), AFB smear density (for 1+ increments; p = 0.03) and 
presence of cavitary disease (OR 3.34, 95% Cl1.33-8.43, p = 0.01) are associated with 2-month 
sputum TB culture positivity in the bivariate analysis. Although statistical significance isn't 
achieved, the presence of anti-tuberculous drug resistance (OR 2.56, 95% Cl 0.94-5.65, p = 0.08) 
and longer duration of TB symptoms prior to presenting to care (for~ 12 weeks of symptoms; 
OR 2.3, 95% Cl 0.94-5.65, p = 0.08) are noted to be an associated with an increased risk of TB 
sputum ex positivity at 2 months of treatment. 
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For the HIV-uninfected subjects in the EM group, those with an increased AFB sputum smear 
density at baseline (for increments of 1+, p<.0001} and those with increased duration ofTB 
symptoms (for~ 12 weeks; OR 2.56 (95% (11.14-5.72, p 0.03} are associated with an .increased 
risk of 2 month TB sputum culture when compared to subjects without these clinical 
characteristics in the bivariate analysis. In the multivariate analysis, increased baseline AFB 
sputum smear density (OR 2.57, 95% Cl1.62-4.1, p <.0001} and longer duration of TB symptoms 
{OR 3.21, 95% Cl 1.27-8.11, p = 0.02} retained significant association with two-month sputum 
culture positivity. 
Objective 3: TB treatment outcome 
Unstratified ana lysis 
For the spot group, those with anti-tuberculous drug resistance at baseline (OR 4.4, 95% Cl 2.02-
9.54, p 0.0002}, cavitary lesions (OR 2.43, 95%CI1.13-5.25} and a longer duration ofTB 
symptoms (for~ 12 weeks; 2.12, 95%CI1.08-4.15, p 0.03} were noted to be more likely to have 
unsuccessful TB treatment outcomes than those who did not have these attributes (see Table 
25}. Attainment of post-secondary school education also had an association with unsuccessful 
treatment outcome {OR 3.79, 95% Cl1.6-9, p = 0.003}. Although not statistically significant, 
there was noted to be a trend towards an association between unsuccessful treatment outcome 
and higher sputum volume category(~ 3ml; OR 2.09, 1.04-4.21, p = 0.06) as well as an older age 
group category(> 40 years of age; p = 0.065}. 
Logistic regression models for the spot group for Objective 3 assessed the relationship between 
baseline characteristics and unsuccessful treatment outcome. The final model included volume 
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category, cavitary lesions, duration ofTB symptoms and post-secondary school education (see 
Table 39) . In the final model, study participants with a baseline sputum volume of ~ 3ml were 
5.76 times as likely to experience an unsuccessful treatment outcome as those with lower 
sputum volume (95% Cl1.6-28.56, p = 0.03). Additionally, duration ofTB symptoms (for~ 12 
weeks; OR 8.07, 95%(11.69-38.59, p = 0.0009) and post-secondary school education 
(attendance of university or technical school; OR 21.03, 95% Cl 2.49-177.55, p = 0.005) had a 
significant association with an unsuccessful TB treatment outcome. 
For the EM group, those with the baseline presence of antituberculous drug resistance (OR 
5.62, 95% Cl 2.67-11.8, p <.0001), cavitary lesions at baseline (OR 2.6, 95% (11.22-5.53, p 0.04), 
longer duration ofTB symptoms(~ 12 weeks; OR 2.6, 95% Cl 1.34-5, p 0.007) and receipt of 
post-secondary school education (OR 2.52, 95% Cl1.12-5.69, p = 0.04) were noted to be more 
likely to have an unsuccessful treatment outcome in comparison to those without these 
characteristics. There was no association noted between volume category and TB treatment 
outcome in the EM group (~3 ml; OR 1.28, 95% Cl 0.66-2.47, p = 0.50). 
In the final logistic regression model for the EM group, volume category, cavitary lesions, drug 
resistance and post-secondary school education were included (see Table 30). Only drug 
resistance (OR 3.4, 95% Cl1.22-9.5, p = 0.02) and post-secondary school education (OR 3.66, 
95% Cl 1.22-11, p = 0.02) retained a significant association with an unsuccessful treatment 
outcome; the relationship between higher sputum volume category and TB treatment outcome 
remained nonsignificant (OR 1.95, 95% Cl 0.77-4.97, p = 0.16). 
As the relationship between post-secondary school education and TB treatment outcome was 
unexpected it was included in a series of univariate analyses (in both the spot and EM groups) 
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with other demographic and clinical/radiograph ic TB markers. In these analyses, post-secondary 
school education had no significant association with HIV serostatus, cavitary disease, duration of 
TB symptoms, AFB _smear grade, retreatment disease, drug resistance or baseline volume 
category. Furthermore, there was no significant association between post-secondary school 
education and study loss-to-follow-up. 
Stratified analysis 
As done for the previous objectives, the spot group fo r Objective 3 was stratified by HIV status 
(n = 91 for the HIV-infected subgroup; n = 105 for the HIV-uninfected subgroup} . In the 
univariate analysis for the HIV-infected spot subgroup, participants with a higher baseline 
sputum volume category (<!3ml} were noted to be 4.43 times as likely to have an unsuccessful 
treatment outcome as those with a low baseline sputum volume category (95% Cl1.34-14.67, p 
= 0.02} . Additionally, the presence of a pulmonary cavity (OR 3.96, 95%(11 .29-12.21, p = 0.02} 
and attaining post-secondary school education (OR 5.25, 95% Cl1_. 53-18.05, p = 0.01} had a 
significant association with treatment outcome . In the logistic regression model conducted for 
this HIV-infected spot subgroup, the final model included volume category(<! 3ml; OR 5.24, 95% 
(11.27-21.48, p = 0.02}, post-secondary school educat ion (OR 6.84, 95% (11.72-27.33, p = 
0.006} and cavitary lesions (OR 3.49, 95% (11.05-11.65, p = 0.04}. These variables were all noted 
to have a significant association with treatment outcome. 
For the bivariate analysis of the HIV-uninfected spot subgroup, no association between volume 
category and treatment association was noted (see Table 30). For this subgroup, age category 
(for~ 40 years of age; p = 0.02}, presence of antituberculous drug resistance (OR 5.87, 95% Cl 
2.14-16.12, p = 0.0008} and days to liquid sputum culture positivity(> 6 days; OR 5.87, OR 0.36, 
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95% Cl 0.15-0.87, p = 0.03) were noted to have a significant association with treatment 
outcome. Attaining post-secondary school education trended towards a significant association 
with unsuccessful TB treatment outcome (OR 3, 95% Cl 0.87-10.08, p = 0.09). 
The EM group was similarly stratified by HIV status (n = 105 for the HIV-infected subgroup; n = 
103 for the HIV-uninfected subgroup). Similar to the spot HIV-infected subgroup, in the EM HIV-
infected subgroup bivariate analysis, those with higher volume category were significantly more 
likely to progress to an unsuccessful treatment outcome than those with a lower baseline 
volume category (OR 3.01, 95% Cl1.11-8.18, p= 0.03). In addition, cavitary lesions (OR 4.41, 95% 
(11.34-14.56, p = 0.01) and attaining post-secondary education (OR 4.23, 95% (11.24-14.37, p = 
0.02) were significantly associated with an unsuccessful treatment outcome . In the final logistic 
regression model for the HIV-infected EM subgroup, only volume category (OR 2.91, 95% Cl 
0.95-8.98, p = 0.06) and cavitary disease (OR 4.47, 95% Cl1.32-15.07, p = 0.02) are retained . 
In the bivariate analysis for the HIV-uninfected EM subgroup, volume category is not associated 
with treatment outcome . Instead, drug resistance (OR 6.62, 95% Cl 2.54-17.25, p <.0001), days 
to sputum culture positivity (OR 2.86, 95% (11.23-6.67, p = 0.02) and duration of TB symptoms 
(~ 12 weeks; OR 2.86, 95% Cl1.23-6.67, p = 0.02) achieve a significant association with 
treatment outcome . 
Assessing variance 
To visually assess the consistency of sputum volume's association with treatment outcome in 
the spot and EM groups (as well as the variability in volume between the two groups), boxplots 
were created (see Appendix, Figure 2). The mean and median of sputum volume for successful 
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and unsuccessful treatment outcome were noted to be dissimila r for the overall spot group as 
well as the spot HIV-infected and EM HIV-infected subgroups (with larger volume mean/median 
in the unsuccessful treatment outcome category for all of the aforementioned groups) . There 
appeared to be no difference in volume mean or median for the overall EM group, spot HIV-
uninfected and EM HIV-uninfected subgroups. There were similar sample variances for all of the 
groups evaluated . In addition, a two-sample t-test was conducted to examine the volume means 
for treatment outcome in the aforementioned samples (see Appendix, Table 3). The F-test of 
equal variance confirmed that there were no differences in variances among all comparison 
groups. The mean baseline sputum volume ofthose participants with successful TB treatment 
outcomes was significantly lower than that of participants with unsuccessful TB treatment 
outcomes in the spot HIV-infected (t = -2 .69, p = 0.009) and EM HIV-infected (t = -2 .11, p = 0.04) 
subgroups; the mean sputum volume trended towards a lower value for those with successful 
treatment outcomes in the overall spot group when compared to those with unsuccessful 
treatment outcomes (t = -2 .07, p = 0.06) . The sputum volume mean was not noted to differ 
significantly between those with successful and unsuccessful treatment outcomes in the overall 
EM group or spot and EM HIV-uninfected subgroups. 
Discussion 
In this secondary analysis of prospective data collected for culture-positive pulmonary TB 
patients, cavitary disease, male gender and HIV infection were associated with a higher baseline 
sputum spot volume category. There was no significant association with sputum spot volume 
and two month sputum conversion in either unadjusted or adjusted analyses, however, a 
baseline spot sputum volume;:: 3 ml is significantly associated with an unsuccessful treatment 
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outcome. Upon stratification of the analysis by HIV status, this association persists in HIV-
infected individuals but not in HIV-uninfected participants. 
Interpretation of results 
Our results show a strong association between spot sputum volume and pulmonary TB 
treatment outcome; study participants with a higher sputum volume category(~ 3 ml) at 
baseline were more likely to develop unsuccessful treatment outcomes than those with a lower 
baseline sputum volume category. This association was also noted in the spot HIV-infected 
subgroup and trended towards a significant association for the EM HIV-infected subgroup as 
well. The absence of this association among the HIV-uninfected subgroups is notable and 
suggests that the presence of an association between increased sputum volume and 
unsuccessful pulmonary TB treatment outcome in the overall sample for baseline spot is 
attributable to the strength of that association in the HIV-positive subgroup. 
The atypical clinical and radiographic presentation of pulmonaryTB in HIV-infected ind ividuals 
has been well-documented6-8; the absence oftypical signs and symptoms ofTB in this sample 
can often delay diagnosis and complicate treatment follow-up . In this study, however, HIV-
infected individuals were noted to have an association with baseline volume category and a 
marker ofTB disease severity (cavitary disease) and-as mentioned-had a significant 
association between higher sputum volume category and unsuccessful TB treatment outcome in 
both univariate and multivariate analysis. The persistence of sputum volume's significant 
association with pulmonary TB treatment outcome in a logistic regression model with other 
potential biomarkers of TB disease severity in the spot HIV-infected subgroup (cavitary disease 
and post-secondary school education) indicates that sputum volume represents a unique aspect 
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of the biological factors contributing to an unsuccessful treatment outcome. The absence of a 
similarly significant association between volume and unsuccessful TB treatment outcome in HIV-
seronegative individuals (in both the spot and EM groups) suggests that this relationship is 
specific to an HIV-infected population. In the presence of an altered immune system with 
dysfunctional cellular response to invasive mycobacterial pathogens, increased sputum volume 
may be one of the few remaining functional bio logical processes that are overtly associated with 
severity of baseline disease, and thus, TB treatment outcomes in the future. 
Of interest, increased sputum volume does not have a significant association (in multivariate 
analysis) with two-month sputum conversion in either the spot, EM or HIV-stratified subgroups. 
Although many previous studies have noted the association between 2-month sputum 
conversion and eventual TB treatment outcomes in developing countries, a recent meta-analysis 
documented that it possessed low sensitivity and modest specificity for predicting TB treatment 
failure and relapse. Furthermore, 2-month sputum conversion was recently removed as a WHO 
indication in the algorithm of determining duration of TB treatment. Although two-month 
sputum sterilization may be an independent risk factor for TB treatment outcome, it is either 
reflects a different biologic pathway than sputum volume (i.e . decrease in bacillary load as 
opposed to underlying inflammation) or precedes any eventual change in sputum volume from 
baseline. 
Despite the small number of post-secondary school attendees in this study (n=47), receiving a 
post-secondary school education was shown to be strongly associated with the development of 
unsuccessful TB treatment outcomes. As noted in the Results section, this was a surprising 
finding and attaining a post-secondary school education did not appear to be a surrogate 
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marker for TB disease severity or treatment adherence. These findings are contrary to a recent 
study evaluating risk factors for unfavorable TB treatment outcomes in Taiwan, which 
documented that higher levels of education had a protective effect against unsuccessful 
treatment outcome26 . The etiology underlying the finding of more highly educated individuals 
experiencing a higher risk of unsuccessful TB treatment outcomes is unknown at this time-
particularly in the setting of a small sample from a secondary analysis of prospectively collected 
data. This result does suggest, however, that there may be differences in access of health care 
services and medications along educational (and potentially socioeconomic) lines in Kampala, 
Uganda. 
Study objectives were analyzed separately by baseline spot and EM sputum volume to evaluate 
the relationship between each collection method, volume values and study objective outcomes. 
As previous studies have shown the higher yield of EM samples (for AFB smear and culture) 27-29 it 
was assumed that EM sputum specimens would be a more sensitive indicator of TB-related 
treatment outcomes than spot sputum. However, only in the spot group was higher sputum 
volume category associated with male gender, cavitary lung disease and HIV serostatus, and the 
relationship between sputum volume and treatment outcomes for Objectives 2 and 3 were 
similar for spot and EM. The reason for differential relationship among sputum volume and 
baseline disease presentation among collection methods is unclear but potentially suggests that 
spot sputum more accurately reflects the of an individual's underlying inflammatory condition. 
The gender imbalance in this study is reflective of the global difference in TB prevalence and 
case notification data between males and females 30.31 . Several biological and social factors have 
been implicated in this differential (gender-based differences in TB susceptibility, health-seeking 
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behavior or access to health care), however recent studies have additionally noted that women 
produce less sputum than men during baseline assessmene2. It has been suggested that this 
difference in sputum volume is attributable to cultural stigma against public female 
expectoration. Regardless of the underlying cause, we note that women in this study were much 
less likely to produce high sputum volumes than men . A recent prospective study evaluated 
South Korean patients with pulmonary TB and noted that sputum volume and gross appearance 
were associated with smear positivity among female patients whereas only gross appearance 
was a pred ictor of smear positivity among male patients33 . Although the re was no associat ion 
noted between sputum volume and either two-month sputum positivity or unsuccessful TB 
treatment outcome when stratified by gender, the association between gender, sputum volume 
and TB outcomes merits further investigation. 
Generalizability 
The study sample was noted to be predominant ly male (63.7% of participants) and had a high 
prevalence of HIV infection (52.3% of participants) as well as a good funct ional performance 
status (82.9% with Karnofsky score> 70); these characteristics are similar t~ previo~sly 
published data .elsewhere in the region30-31'34 and, are indicative of pat ient s presenting for TB 
treatment in Uganda. 
Although the study sample was largely male, women were noted to have a higher prevalence of 
HIY infe<;:t ion (7_1% of females) than men (41.5% of males; see Appendix Table 2) . Th is 
observation has been consistently documented in previous Ugandan studies35-37 as well as the 
sub-Saharan continent in general38-39 . . This gende.r differential in HIV in.fe ~tion is th~ught to be 
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seconda~y to differences ·intransmiss,ion r-ates or longer survival among HIV-infected·women 
. . ' ' . . . . . 
compared to HIV-infected men. 
As for internal validity, it has been previously noted that the study sample is not entirely· 
homogenous. Although there are participants who overlap for both sputum collection groups 
and those who are only included in either the sputum or EM groups for each objective, 
however, these subjects do not significantly differ from each other in baseline characteristics . Of 
note, increased baseline spot sputum volume for HIV-infected patients was noted to be 
significantly associated with male gender and cavitary lung disease. Therefore, HIV-infected and 
-uninfected individuals appear to have significant differences in some baseline characteristics 
and the study outcome results for one group may not be representative of the other. The study 
analysis has accounted for this baseline difference by stratifying the analysis of Objectives 2 and 
3 on HIV serostatus. 
In order to evaluate defined endpoints (2 month sputum positivity and unsuccessful TB 
treatment outcome) study participants without positive baseline sputum culture were excluded 
from this analysis. The study results may therefore be inapplicable to those diagnosed with 
pulmonary TB based on clinical or radiographic parameters alone. Furthermore, in settings 
where sputum is routinely induced, the results of this study will be meaningless as only 
spontaneously expectorated sputum specimens were analyzed. 
Based on the programmatic setting, satisfactory sample size and high HIV prevalence, we 
believe that the study results are generalizable to pulmonary TB patients in resource-limited 
settings with high HIV endemicity, 
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Limitations 
There are certain limitations inherent to this study due to its observational design; these 
limitations include potential measurement bias. It is acknowledged that this study's 
interpretation of study results relies on an accurate quantification of baseline sputum volume 
for study participants. If sputum volume values were inconsistently measured by different 
observers, variability in study results and potential bias (in either direction) could occur and 
render the conclusions reached from study results inaccurate. This bias is limited by the 
previously mentioned technique of routine referral to a reference container's gradation by 
trained laboratory technicians, nevertheless, we cannot exclude that small deviations from the 
true volume value may have occurred on several occasions. 
Selection bias could also occur if those individuals who chose not to participate in the study 
were more ill than the study participants and had worse treatment outcomes than was 
documented; our results for the association between sputum volume and treatment outcome 
would then be inappropriately biased towards the null. To a lesser extent, recall bias (due to 
potential for participant inexactitude when reporting duration ofTB symptoms prior to 
diagnosis) may lead to distortion of study results if there was differential estimation of TB 
symptom duration. 
In this analysis, we expected to see a significant association between retreatment TB disease 
and unsuccessful TB outcome. The absence of such an association may be attributable to the 
low numbers of non-retreatment cases (and therefore, the lack of a sufficient comparison 
group) as well as the NTLP clinic's policy of administering MDR-TB treatment on an outpatient 
basis. In the latter case, if retreatment TB cases who are potentially more ill than enrolled 
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patients are omitted from the study, the association between retreatment TB and treatment 
outcomes will shift towards the null. Similarly, the effect of excluding most of those patients 
with known MDR-TB at time of diagnosis is likely to have biased the association between 
antituberculous drug resistant TB cases and treatment outcome towards the null as the patients 
with the most extensive drug resistance (and thus, increased risk for unfavorable treatment 
outcomes) are not included. 
As this study only included sputum cult ure-positive subjects, study findings on the association 
between TB treatment outcome and sputum volume may not be applicable in resource-poor 
settings where smear-negative patients are diagnosed and treated for presumed TB based on 
clinical or radiographic features alone. 
Clinical Applicability/Recommendations 
Our research contributes to the understanding of increased sputum volume as a potential 
predicto r of unsuccessful TB treatment outcome. The measurement of sputum volume has 
previously been assessed as a modifiable factor by which to improve the detection of AFB by 
sputum microscopy, but has not previously been evaluated-in isolation-as a predictor of 
disease status and treatment outcome. Previous evaluation of potential biomarkers such as 
sputum smear grade or time to detection of mycobacteria in culture have failed to show 
evidence of an association with baseline disease severity or treatment outcome34.4° . In this 
study, greater sputum volume {:2: 3 ml) has emerged as a potential risk factor for unsuccessful 
treatment outcome, particularly for HIV-infected populations. 
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As previously noted, HIV-infected populations are noted to have worse TB-related treatment 
outcomes than HIV-uninfected groups and often present with atypical signs of disease that can 
make treatment and follow-up difficult. Therefore, the clinical utility ofthis study will be 
greatest for HIV-infected individuals. Those HIV-infected patients with larger sputum volumes(;::: 
3mL) produced at the time of diagnosis should be monitored closely to ensure that treatment 
failure or relapse does not occur. 
There appears to be no significant difference in the association between sputum volume and TB 
treatment outcome among collection methods (for spot or EM) . Due to the relative ease and 
time savings of obtaining a spontaneously expectorated spot sample, however, we recommend 
that any evaluation of sputum volume for TB treatment outcomes be performed on spot 
specimens. Until more studies are performed, no recommendations can be made to change the 
duration of antituberculous therapy based on baseline sputum volume. 
As an aside, our study unexpectedly showed a relationship between post-secondary school 
education and unfavorable TB treatment outcomes. The documentation of this relationship in 
this study warrants further investigation, as it is contrary to the commonly established link 
between expanded access to education and improved public health outcomes in developing 
regions. 
Conclusion 
The determination of treatment regimens and duration among pulmonary TB-infected 
individuals in resource-limited settings is complicated by the difficulty of determining patients' 
risk for unsuccessful treatment outcome. Potential surrogate markers ofTB treatment 
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effectiveness and clinical prognosis (such as two-month sputum conversion) have been used but 
have exhibited poor performance characteristics. Both the assessment of clinical severity and 
the evaluation of clinical prognosis are complicated in the TB/HIV-co-infected patient, for whom 
treatment outcomes, morbidity and mortality remain poor. 
In this study, an increased baseline sputum volume was noted to be associated with increased 
disease severity and with unsuccessful TB treatment outcomes in sputum culture-positive, HIV-
infected individuals receiving antituberculous therapy in Kampala, Uganda. Sputum volume 
measurement (particularly spot sputum volume) is inexpensive, quick, readily evaluable and can 
easily be built into a microbiology laboratory's work-flow. Identifying at-risk patients through 
quantification of sputum volume may assist in optimizing treatment duration and cure-
particularly in HIV co-infected patients for whom effective TB treatment outcome predictors are 
lacking. There is a need for further studies to confirm the relationship of sputum volume and TB 
treatment outcome in HIV-infected and -uninfected . 
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Figure 1. Inclusion/ 
Exclusion Flowsheet 
Appendix A 
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Table 1. Univariate association between baseline sputum volume and baseline characteristics of 296 
hospitalized TB patients in Kampala, Uganda by first spot sputum measurement. (Objective 1) 
Characteristic 
Age 
Gender 
Weight category 
Cavitary disease 
.. ·-·· 
Miliary infiltrate 
Adenopathy 
B/1 Lung 
infiltrates 
Duration of TB 
symptoms 
Night sweats 
Fever 
Cough 
Hemoptysis 
Karnofsky score 
HIV status 
Level Low Volume 
(%)(n=168) 
High Volume OR 
(%)(n= 130) (95% Cl) 
<30(n = 11~) _ -- ~0 (54) .... . __ __ _ 51 (46) 
55[43.32 _1_·?. (0 :?~ :?:29) 1.08 (0.58-2.03) 
1 
30-40 (n= 127) 72 (56.7) 
>40 (n=58) 3~J~?·§L 
Female (n=l07) 73 (68.2) 
Male (n=~?~} ____________ .~3 {_~9 . 2)_ _ 
::; 50 kg (n = 166) 96 (57.8) 
>SOk~ (r1~130) 70 (5 3.:?l . .... . 
Absent (n = 96) 66 (68.7) 
Pre ?._~nt(r~ ::; 165) .......... 80(48:?1 
Absent (n = 266) 147 (55.3) 
~resent(~ ~ ~) 1 ~ 100) 
Absent (n = 239) 132 (55.2) 
Present (n :;: p) .... ~-4 (63.6) 
Absent (n = 100) 62 (62) 
Present _(n = 179) 8?(?._9.) _ 
<12 weeks (n = 75 (58.1) 
129) 
<:: 12 weeks (n = 
~~7) 
Absent (n = 90) 
Present(r! :;: ?O~) 
Absent (n = 178) 
Pr~sent (n = 11~)_ _ 
Present (n = 290) 
AbsentJr~ = 6) ... 
Absent (n = 274) 
Pres~ nt (n = 22) .. 
QO(n=53) 
~_70(n =24~). 
Uninfected ( n = 
149) 
Infected (n = 147) 
91 (54.5) 
45 (SO) 
~21(58:?! 
98 (55.1) 
68 l57:6) ... 
5 (55.5) 
!§~J83 }) . 
155 (56.6) 
11 (SOJ ....... . 
34 (64.2) 
}?2J?4:~) 
94 (63.1) 
72 (49) 
34 
- ·- .?~J41.- 4) 
34 (31.8) 
92._{50.~) . 
70 (42.2) 
60_ (~6 . 2) 
30 (31.3) 
........ 85(?1.5) _ 
119 (44.7) 
0(9) ..... 
107 (44.7) 
8 (~.6.4) 
35 (38) 
85 (SO) 
""54 (41.9) 
76 (58.5) 
45 (50) 
.......... 85(~~: 3) . 
80 (44.9) 
50J42.4) 
1 (44.5) 
129 (16.7) 
.... "i19 (43.4) 
11 JSO) 
19 (35.8) 
.!.!~(45 . 7) 
55 (36.9) 
75 (51) 
2.22 (1.35-3.64) 
1.18 (0.74-1.87) 
2.23 (1.38-4) 
N/A 
0.70 (0.29-1.74) 
1.63 (0.99-2. 7) 
1.16 (0.73-1.84) 
0.7 (0.43-1.16) 
0.90 (0.56-1.44) 
0.25 (0.03-2.16) 
·········-
1.3 (0.55-3.11) 
1.51 (0.81-2 . 78) 
1.78 (1.12-2.83) 
p 
value 
0.83 
0.87 
0.002 
0.56 
0.002 
1 
0.51 
0.06 
0.56 
0.21 
0.72 
0.23 
0.66 
0.22 
0.02 
Table 2. Logistic regression -derived Odds Ratio for cavitary disease category variable in 296 hospitalized 
TB patients in Kampala, Uganda by first spot sputum measurement. (Objective 1) 
Variables in Cavitary disease Percent change in Order added to Logistic Regression 
Model category OR Odds Ratio Model in model building procedure 
Cavitary disease 2.34 
Cavitary disease 2.06 12% 1 
and gender 
35 
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Table 3. Multivariable association between baseline sputum volume and baseline characteristics of 296 hospitalized TB patients in 
Kampala, Uganda by first spot sputum measurement. (Objective 1) 
Model Factor Level AIC1 Adjusted OR2 
(95% Cl}3 
(-
statistic 
1 Model 351.8 0.60 
. ____ ,,_ ..... , . . ·-·-"-'·- - ·- ·-··" ·""-· '·---~--- --·-·- ·· · --··- -- - ·-~---·-
Cavitary Present 2.34 (1.38-4) 
disease 
2, Model 
Fjnal ·····- · --·-··-···· 
Cavitary 
disease Gender - -- ·-· 
346.6 
Present 2.06 (1.2-3 .54) 
Male 2.1 (1.22-3.62) 
0.64 
Hosmer- Hosmer- Model %Change in Decision 
Lemeshow Lemeshow p- Adjusted OR 
test p-value value 
0 
. - _ n.{~ _ 0.60 
0.60 
0.001 0.99 
0.009 
0.008 
C1'l 1AIC =Aka ike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
Table 4. Bivariate association between baseline sputum volume and baseline characteristics of 360 
hospitalized TB patients in Kampala, Uganda by first early morning sputum measurement. {Objective 1} 
Characteristic Level Low Volume High Volume OR p value 
(n= 140) (n= 220) (95%CI) 
Age 
<30 (n = 134) 57 (42.5) 77 (57.5) 1.48 (0.81-2.69) 0.42 
... 
30-40 (n= 15~}_ 58 (37.7) 96 (62.3) 1.21 (0.67-2.18) 0.1 
>40 (n=72) 24(66.7) 48 (33.3) 1 
Gender Female (n = 130) 55 (42 .3) 75 (57.7) 0.78 (0.51-1.22) 0.31 
Male (n = 230) 84 (36.5) 146 (63.5) 
Weight Category ~ 50 kg (n = 194) 81 (41.8) 113 (58.2) 1.33 (0.87-2.05) 0.19 
>50 kg (n =15.6) 58 (34.9) 108 (65.1) 
... 
Cavitary disease Absent (n = 96) 47 (39.2) 49 (60.8) 0.67 (0.39-1.15) 0.17 
Present (n = 125) 49 (51) 
. ? .6.(49) 
Miliary infiltrate Absent (n = 231) 97 (42) 134 (58) 1.45 (0.13-16.19) 1 
Present (n = 3) 1 (33.3) 2 (66.7) 
Adenopathy Absent (n = 201) 84 (41.8) 117 (58.2) 0.48 (0.19-1.22) 0.16 
Present (n = 20) 12 (60) 8 (40) 
Bilateral lung Absent (n = 145) 57 (39 .3) 88 (60.7) 1.09 (0.69-1. 71) 0.73 
infiltrate Present (n = 1]4) 65 (37.4) 109 (62.6) 
Duration of TB ~ 12 weeks (n = 54 (34.6) 102 (65.4) 0.74 (0.48-1.14) 0.19 
symptom 156) 
category >12 weeks (n = 85 (41.7) 119 (58.3) 
294) 
................. m•••--• 
Night sweats Absent (n = 106) 43 (40.6) 63 (59.4) 0.89 (0.56-1.41) 0.63 
Present (n = 254) 96 (37.8) ·--~~8 (62.2) 
Fever Absent (n = 211) 86 (40.8) 125 (59.2) 1.25 (0.81-1.92) 0.33 
Present (n = } _4:9) 53 _(35.6) 96 (64.4) 
Cough Absent (n = 6) 4 (66.7) 2 (33.3) 3.24 (0.59-18) 0.21 
Present (n = 354) 135 (38.1) -~ 19 (61.9) 
Hemoptysis Absent (n = 332) 129 (38.9) 203 (61.1) 1.14 (0.51-2.56) 0.84 
Present (n = ?~) 10 (~5.7) 18 (64.3) 
Karnofsky score ~ 70 (n = 53) 25 (47.2) 28 (52.8) 0.66 (0.37-1.19) 0.17 
>70 (n = 307) 114 (37.1) 1.~3 (62.9) 
HIV status Uninfected (n = 73 (39.9) 110 (60.1) 1.11 (0.72-1.69) 0.67 
183) 
Infected (n = 176) 66 (37.5) 110 (62.5) 
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Table 5. Logistic regression-derived Odds Ratio for positive cough category variable in 360 hospitalized TB 
patients in Kampala, Uganda by first early morning sputum measurement. {Objective 1) 
Variables in Model Cough category Percent change in Order added to Logistic Regression 
OR Odds Ratio Model in model building procedure 
Cough 3.24 
Cough and 1.8 44.4% 1 
adenopathy 
38 
w 
1.0 
Table 6. Multivariable association between baseline sputum volume and baseline characteristics of 360 hospitalized TB patients in 
Kampala, Uganda by first early morning sputum measurement. (Objective 1} 
Model Factor Level 
1 Model 
AIC1 Adjusted OR2 C-statistic 
(95% Cl)3 
482.3 0.51 
Cough Present 3.24 (0.59-18) 
Model 305.9 0.53 
Cough Present 
f..Cieno-llathvPr-e5ent 
1AIC =Aka ike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
----~~jQ.15-21 . 9] ___ ... ..... 
0.5 (0.19-1.32) 
Hosmer-
Lemeshow 
test 
0 
0.07 
Hosmer- Model %Change in Decision 
Lemeshow p- Adjusted 
p-value value OR 
n/a 0.18 
n/a 0.27 4 Keep in 
model 
~----·-··---··---··-'-----· -------·-----···--· 
0.65 
0.16 
Table 7. Bivariate association between baseline sputum volume and baseline characteristics of 149 
hospitalized HIV seropositive TB patients in Kampala, Uganda by first spot sputum measurement. 
{Objective 1) 
Characteristic Level Low Volume High Volume OR p value 
(n=94) (n= 55) (95% Cl) 
Age 
........ , .... _ •···· . . 
<30 (n =. 34) . 24 (70.6) 10 (29.4) 0.93 (0.31-2.72) 0.36 
30-_40 (n= ~6) 
. .. 
_so (5?,.11 . 3§ (~1.9) .... .. ~ .6 (0.65-3.92.) 0.38 
>40 (_~=29) 20 (69) 9 13~L 1 
Gender Female (n=71) 52 (73.2) 19 (26.8) 2.35 (1.18-9.67) 0.02 
Male (n=78) 42 (?3.9) 36 (46.1) . 
Weight category ::; 50 kg (n =54) 31 (57.4) 23 (42.6) 0.68 (0.34-1.36) 0.29 
>59k~ (n=. 9.5) _ ~3 (66:3) 
·····-···· 
32 !~3 : 7) 
Cavitary disease Absent (n = 76) 54 (71.1) 22 (28.9) 2.46 (1.18-5.12) 0.03 
Pre_sent (11 =.52) ~6 (?O) 26 (5Q} ' .. 
.. i 
Miliary infiltrate Absent (n = 131) 81 (61.8) 50 (38.2) N/A 1 
Pre~ent(n = 1) .... 
.... 
1 (100) 0 (0) 
. ... -.. 
Adenopathy Absent (n = 109) 67 (61.5) 42 (38.5) 0.74 (0.26-2.09) 0.62 
Pr_e_se!:l t (n =_19) 13 (68.4)_ 6 (~1.6J 
Bilateral Lung Absent (n = 56) 37 (66.1) 19 (33.9) 1.65 (0.8-3 .39) 0.21 
infiltrates Present (n = 72) 3~j54.3) 33 J45.~) 
.. ~-
<.12 weeks(~ = GS) .... Duration of TB 41 (63.1) 24 (36.9} 1 (0.51-1.96) 1 
symptoms ;::: 12 weeks (n = 84) 
.. -~ A -
53 (63.1) 31J36.9) 
Night sweats Absent (n = 43) 25 (58.1) 18 (41.9) 0.74 (0.36-1.54) 0.46 
Present (n = ~06) 69 (65.1) 37 (34.9) 
Fever Absent (n = 48) 31 (64.6) 17 (35.4) 1.1 (0.54-2.25) 0.86 
P ~ese~~.lr1 . = !9~) ... 
····· 
6? (62.:4) 
..... 
~~ - (3J.§l . 
Cough Absent (n = 4) 4 (100) 0 (O) N/A 0.3 
Pr~se~_t (n =._ 1~5) 90 (62.1) 55 (37.9) 
.. 
Hemoptysis Absent (n = 141) 90 (63.8) . 51 (36.2) 1.77 (0.42-7.36) 0.47 
......... 
.. P~es_el)! (D. = 8) . 4(5QL ... . ... 4 (?.Q). ' 
Karnofsky score :570 (n = 110) 68 (61.8) 42 (38.2) 0.81 (0.38-1.75) 0.70 
>70 (n = 39) 26 (66.7) 13 (33.3) 
40 
Table 8. Logistic regression-derived Odds Ratio for cavitary disease category variable in 149 hospitalized 
H IV seropositive TB patients in Kampala, Uganda by fi rst spot sputum measurement. (Objective 1) 
Variables in Model Cavitary disease Percent change in Order added to Logistic Regression 
category OR Odds Ratio Model in model building procedure 
Cavitary disease 2.45 
Cavitary disease 2.29 6.5% 1 
and gender 
41 
Table 9. Multivariable association between baseline sputum volume and baseline characteristics of 149 hospitalized HIV seropositive TB 
patients in Kampala, Uganda by first spot sputum measurement. (Objective 1) 
Model Factor Level AIC1 Adjusted OR2 C-statistic Hosmer- Hosmer- Model %Change Decision 
{95% Cl)3 Lemeshow Lemeshow p-value in Adjusted 
test p-value OR 
1 Model 167.5 0.61 0 N/A 0.02 
-------·--. ·-----_....____ __ . ·~·- --·--· --------- ---....___ ___ ~-- ~-_......,_.:. _ ______ ____..o~.·;..~ ___ __.___...__-L,.._~-------·-· 
Cavitary Present 2.45 {1.18-5.12) 0.02 
disease 
2 Model 164.2 0.66 0 .39 0 .82 0.004 6.5% Remove 
from 
model 
I 
.j:::. i.~- ~--- . --- ~·~=--..........,;;,~- -----~~-- -~~·---~-----~~-----~·~--, __ ..._ ___ _ _..:.:... .......... ~--~--:........:WO.·· ...... ----__.------- __ _. -~---- - -- --- • -·---- -~-:..._ ... _, ______ _._ --- ~ .. _________ __ ....... ______ ;..._ ____ .. -~ .. -
N Cavitary Present 2.29 {1.08-4.86) 0.03 
disease 
.,. . ...........,. _ _ .. ,.,...,.. . • _.. •.. ._.. .. - .. ......--...-"'!l2"':--~""'' ', 2.41 (f"B-5"15)~·-~-··-~- -···~. -·· Gender Present 0.02 
Final Model 167.5 0.61 0 N/A 0.02 
2.45 (i18-s .12l- . ~ Cavitary Present 0.02 
disease 
Table 10. Bivariate association between baseline sputum volume and baseline characteristics of 147 
hospitalized HIV seronegative TB patients in Kampala, Uganda by first spot sputum measurement. 
(Objective 1} 
Characteristic Level 
Ag~ 
Gender 
Weight 
cate~()ry 
, Cavitary 
disease 
Miliary 
infiltrate 
Adenopathy 
. 
Bilateral Lung 
infiltrates 
Duration of TB 
symptoms 
·~-- -~ 
Night sweats 
Fever 
Cough 
Hemoptysis 
Karnofsky 
score 
<30 (n = 77) 
~0~40(~= 29) 
>40 (n=41) _ 
Female (n= 36) 
Male(ry=111} _ 
::; 50 kg (n = 71) 
>50 kg (n= 76) 
Absent (n = 2oj ·· 
. Pr~s~ntj n =11~) 
Absent (n = 135) 
Present Jn ~. 9l 
Absent (n = 130) 
Present Jn = 3) 
Absent (n = 44) 
Present (n = 98) 
<12 .;.,eeks (n = ·64)' 
:::: 12 weeks (n = 83) 
Absent (n = 47) 
Present (n = 100) 
·Absent (n = 7o) -
_ ... P_rese~t (n =7?) 
Absent (n = 2) 
Pres~ nt (n = 145) 
Absent (n = 133) 
Present (n = 14) 
::;70 (n = 133) 
>70 (n = 14) 
Low Volume 
(n=72) 
41 (53.3) 
--- ~~J -~6~?L 
15 (51.7) 
21 (58.3) 
51 (46) 
38 (53 .5) 
37 (48.7) 
........................ 
8 (40) 
59 {:52:..?) -
69 (51.1) 
0 (0) . 
65 (SO) 
High Volume OR 
(n= 75) (95% Cl) 
36 (46. 7) 
•. • ..... ·~"¥' 
.. ?2(~_? : 7) 
14 (48.3) 
15 (41.7) 
... 
.... 0.94 (0.40-2.21) 
.. 1.24 (Q_.48-3.22) 
1 
1.65 {0.77-3.52) 
. §0 (54 l.~---------'-
33 (46.5) 1.21 {0.65-2 .32) 
?.9 (?1.3) 
12 (60) 
- ~4 l47.~) .. 
66 (48.9) 
0 (O) 
65 (SO) 
N/A 
0.5 {0.04-5.65) 
2 (66J)_ 
19 {43.2) 
-· --· _1 (33 .3) .... 
25 (56.8) 
.. 
0.67 {0.33-1.38) 
-=~~ -(~~ - 1) __ 
30 (46.9) 
.. - _4~ (_?~ . 2) 
27 (57.5) 
48.(~8) .... 
33 (47.1) 
4? _(5_4~?1 
1 (SO) 
74 (51) 
7 (SO) 
§~JSL_~) _ 
69 (51 .9) 
6 (42.9) 
43 
46 (46.9) 
34 (53 .1) 0.75 (0.39-1.43) 
38 (45.8), __ _ 
20 (42 .5) 1.46 {0.73-2.94) 
52 (52) 
37 (52.9) 
........ ~.?. (~?-~). 
1 (SO) 
71 (49) 
7 (SO) 
_ §S (48.9.) _ 
65 (48.1) 
8 (57.1) 
0.74 {0.39-1.42) 
.. 
0.96 (0.06-15 .63) 
1.44 {0.47-4.37) 
p value 
0.82 
0.81 
0.25 
0.62 
N/A 
1 
0.36 
0.41 
0.30 
0.41 
1 
0.58 
Table 11. Logistic regression-derived Odds Ratio for male gender variable in 147 hospitalized HIV 
seronegative TB patients in Kampala, Uganda by first spot sputum measurement. {Objective 1) 
Variables in Model Male gender OR Percent change in Order added to Logistic Regression 
Odds Ratio Model in model building procedure 
Adenopathy 0.5 
44 
~ 
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Table 12. Multivariable association between baseline sputum volume and baseline characteristics of 147 hospitalized HIV seronegative 
TB patients in Kampala, Uganda by first spot sputum measurement. (Objective 1) 
Model Factor Level AIC1 Adjusted OR2 C- Hosmer- Hosmer- Model %Change Decision 
(95% C1)3 statistic Lemeshow Lemeshow p-value in 
test p-value Adjusted 
OR 
., 1, Firial Model . . . 188 . 0.51 0 n/a 0.56 n/a 
--- --~·· -· ~· --·······----........._~- ------~--......_--·--·-------· ··----- ................ .,,........_~-------- ............... _ __ __,__,_ __ ,__ ________ ..._ _____ ,_" __ ._ ............... __ • ___ .c.....;..-._ ________ ~----~-. ---'--~ .. -------··--' 
Adenopathy Present 
1AIC =Aka ike's Information Criterion 
20R = Odds Ratio 
395% Cl = 95% Confidence Interval 
0.5 (0.04-5.65) 0.56 
Table 13. Univariate association between baseline sputum volume and baseline cha racteristics of 183 
hospitalized HIV seropositive TB patients in Kampala, Uganda by first early morning sputum 
measurement. {Objective 1) 
Characteristic level low Volume High Volume OR p value 
(n= 73} (n= 110} (95% Cl} 
j\g~ 
......... . .. 
<30 (n = 45) 24 (53.3) 21 (46.7) .1.55 (0.63-3 .8) 0.54 
} Q-4q (n:: .! 9?) 63 (_61_._8) 
..... 
39 (?8.2) 1.1_(9:5_-2.41) 0.89 
>40 (n=36) 23 (63.9) 13 (36.1) 1 
Gender Female (n;, 89) 39 (41.5) 55 (58.5) 1.15 (0.63-2.04) 0.65 
.... 
Male(!)= 94) 
~-- .. 
3~ (3?:?l 55 (6.1. ~ ) 
Weight Category ~ 50kg(n = 113) 69 (61.1) 44 (38.9) 1.11 (0.6-2.04) 0.76 
>SQ. .k~ .. (n.= 79) 41 (58.6} 
.............. 
2~ (~~:4L . 
. ... 
Cavitary disease Absent (n = 74) 38 (51.4) 36 (48.6) 0.54 (0.26-1.14) 0.14 
Presel)t ( ~ = ~0). ... 23 _( 6~) - ·- .... ) ?(:34) 
Miliary infiltrate Absent (n = 130) 76 (58.5) 54 (41.5) 0.7 (0.06-7.86) 1 
Pr~s~ ~t (n.:::. :3) . 2 (66.7) 1 (33.3) 
..... .. ........ , .. ........ , ....... ~-- .. .... .............. 
Adenopathy Absent (n = 104) 63 (60.6) 41 (39.4) 2.3 (!).87-6.12) 0.14 
... 
Pr~sent(n :::: ?Q) 
--- _8 (~0) 
-
12 i60)_ 
Bilateral lung Absent (n = 69) 40 (58) 29 (42) 0.77 (0.4-1.47) 0.50 
infiltrate ~r~.se.n~ (~ =8_4) .... ?4(6~.3) _?O (?5.7) 
Duration of TB ~ 12 weeks (n = 82) 55 (67.1) 27 (32.9) . 1.7 (0.93-3.12) 0.1 
. symptom >12 weeks (n = 101) 
categ'?ry 55(?4.~) .- 46 (45_.5) 
Night sweats Absent (n =53) 30 (56.6) 23 (43.4) 0.82 (0.43-1.56) 0.62 
Present (n = 130) 80 (61.5) so (38.5) 
.. 
Fever Absent (n = 64 39 (60.9) 25 (39.1) 1.05 (0.57-1.96) 1 
~re.sent (n = 119) _ ... 
... 
7! (~9. 7 ) 
.. ... 
. ~~(~Q.3)_ 
-
Cough Absent (n = 4) 1 (25) 3 (75) 0.21 (0.02-2.1) 0.30 
Present (n = 179) 109 (60.9) 70 (39.1) 
.. ... 
Hemoptysis - Absent (n = 172) · 104 (60.5) 68 (39.5) 1.28 (0.37-4.34) 0.76 
Prese.nt{ n ::: 11) .9 (5~.6) - ? (4?.4)_ 
Karnofsky score ~ 70 (n = 147) 93 (63.3) 54 (36.7) 1.92 (0.92-4.02) 0.09 
>70 (n = 36) 17 (47.2) 19 (52.8) 
46 
Table 14. Logistic regression-derived Odds Ratio for baseline cough variable in 183 hospitalized HIV 
seropositive TB patients in Kampala, Uganda by first early morning sputum measurement. (Objective 1} 
Variables in Model Positive baseline Percent change in Order added to Logistic Regression 
cough OR Odds Ratio Model in model building procedure 
Cough 0.21 
Cough and 0.53 60% 1 
adenopathy 
Cough and 0.25 19% 2 
Karnofsky score 
47 
Table 15. Multivariable association between baseline sputum volume and baseline characteristics of 183 hospitalized HIV seropositive TB 
patients in Kampala, Uganda by first early morning sputum measurement. {Objective 1} 
Table 16. Bivariate association between basel ine sputum volume and baseline characteristics of 176 
hospitalized HIV seronegative TB patients in Kampala, Uganda by first early morning sputum 
measurement. (Objective 1) 
Characteristic Level Low Volume High Volume OR p value 
(n= 66) (n= 110) (95% Cl) 
A.ge 
<30 (n = 89) 53 (S9.6) 36 (40) 0.59 
··-
30-~0. (£1.=5~) 
····--
................. ~.? (§2- ?) --~~_(37.: ?.l .. - ~ ·3? (0:54-3.35) -
_:>40 (n=3~) 25 (69.4) 11 (30.6) 1 
Gender Female (n = 41) 21 (S1.2) 20 (48.8) 2.1 {1.03-4.27) 0.04 
... 
__ M_ale (n =. 13~) _ .45(}3.3) . 90 (6.6} ) -
Weight Category :::; 50 kg(n = 81) 44 (54.3) 37 (4S.7) 0.52 (0.28-0.97) 0.04 
..... 
>.5_9k~(~ = ~5) 
.... - .. ~§(1)~.5) ?.9 (~O.S! 
Cavitary disease Absent (n = 21) 10 (47.6) 11 (52.4) 1.48 (0.56-3.9) 0.47 
~rese !1t (n ::= 7~) 
- " - ~3 __( 57.~ 32 (42.7) 
Miliary infiltrate Absent (n = 100) 57 (47) 43 (43) N/A N/A 
.. 
Prese~t (n_= 0) 
... 
9. (9.) q (9.L .. . 
Adenopathy Absent (n = 96) 53 (55.2) 43 (44.8) N/A N/A 
PresE!nt (0 =:=. 0)_ 0(0) 0 (0) 
Bilateral lung Absent (n = 76) 48 (63.2) 28 (36.8) 1.11 (0.59-2.09) 0.75 
infiltrate ~r e_s~~t (n._ = 89) ... 54:.(60.7) 35 (39.3) 
... 
Duration of TB !> 12 weeks (n = 73) 46 (63) 27 (37) 
symptom >12 weeks (n = 103) 
categ~ry_ 
-
~4J6?. 1l 39 .(37.92_ 
Night sweats Absent (n =53) 33 (62.3) 20 (37.7) 0.99 (0.51-1.92) 1 
Pr_esent (n ~ 123) 77 (62.6) 4_6 (37~4) 
Fever Absent (n = 84) 56 (66.7) 28 (33.3) 1.41 (0.762 .6) 
Pres.~n.t (n =. 92) ... 54 (!)8.7) ~~- (41.3) 
'" .......... 
Cough Absent (n = 2) 1 (SO) 1 (SO) 0.60 (0.04-3 .7) 1 
Presen.t (n = 174) 109 (62.6) 65 (37.4) 
..... - -- ... -
Hemoptysis Absent (n = 159) 98 (61.6) 61 (38.4) 0.67 (0.22-1.99) 
presen~ (n = 17) ~.?. (7Q.6) ... 5 (29.f!)_ 
- ··-
O•m•-•-
Karnofsky score :::; 70 (n = 159) 99 (62.3) 60 (37.7) 1.11 (0.39-3 .16) 1 
>70 (n = 17) 11 (64.7) 6 (35.3) 
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Table 17. Logistic regression-derived Odds Ratio for male gender variable in 270 hospitalized HIV 
seronegative TB patients in Kampala, Uganda by first early morning sputum measurement. (Objective 1) 
Variables in Positive baseline Percent change in Order added to Logistic Regression 
Model cough OR Odds Ratio Model in model building procedure 
Male gender 2.1 
Male gender and 1.94 7.6% 1 
weight category 
50 
LT1 
1-' 
Table 18. Multivariable association between baseline sputum volume and baseline characteristics of 176 hospitalized HIV seronegative 
TB patients in Kampala, Uganda by first early morning sputum measurement. (Objective 1) 
Model Factor level AIC1 Adjusted OR2 C-statistic Hosmer- Hosmer- Model 
(95% Cl)3 lemeshow lemeshow p-
test p-value value 
. 1 Model 232.7 0._57 ~--~· ..!}_ ______ ~- N/ ~--~ .. ~~~'! ---~-<-..:.>U:~....-:.&,....~~-
Gender Male 2.1 (1.03-4.27) 0.04 
2 Model 231.4 0.62 1.63 0.44 0.02 
>..........c..__.-. .-......~:.r.:...~.--- ., .. "'-.A.~"---""'-'-'---·-,.__• ·~--...M..-'-······....-:o:&.---.._....___,,_,~~ •• ~~--•·-···-·....:.; .• _ , __ _._~.~~-~-~· -~-........ ----···--·-··-·-· ·---~-·-----·-·--· .. ---"'"••·--·-··••• 
Gender Male 1.94 (0.94-3.98) 0 .07 
_ .. _·~-~·-we ight ;~-~-·~~-0_.56(CJ:3-l.05) ·-~~--~p . - ... ...........,......,...,.~---.-.r_..,.~-. 0.07 
category kg 
Final Model 232.7 0.57 0 N/A 0.04 
_., . __ -~ _,.---=-·-,...-- 2.1 (1.03-4z 7)"- ~·-··· ~--·---·---~ _____ .. ____ -- -- ·-- ... - · · --5.64 
~ Gender Male 
1AIC =Aka ike's Information Criterion 
20R = Odds Ratio 
395% Cl = 95% Confidence Interval 
% Change in Decision 
Adjusted OR 
7.6% Remove 
from modeL 
--
Table 19. Bivariate association between two month sputum culture positivity and baseline characteristics 
in 270 hospitalized TB patients in Kampala, Uganda according to spot sputum volume status. (Objective 2} 
Characteristic Level Negative Positive culture OR (95% Cl) p value 
culture (n = 153; 
(n =117; 56.7%) 
43.3%) 
Volume Low(< 3 ml; n = 48 (46.6) 55 (S3.4) 1.24 (0.76-2.03) 0.45 
category 103) 
High(~ 3ml; n = 69 (41.3) 48 (S8.7) 
167) 
~--· 
Age <30 (n = 100) 40 (40) 60 {60) 0.92 (0.46-1.85) 0.86 
30-40 (n = 120) 58 {48.3) 62 {S1.7) 0.66 (0.33-1.29) 0.25 
>40 (n =50) 19 {38) 31 (62) 1 1 
~- ~ . -·· ... ... 
Gender Female (n = 97) 48 (49.S) 49 (SO.S) 1.48 (0.89-2.44) 0.16 
... 
Male (f1= 173) 
...... 69_(3_9.~) 104_(60.~) 
HIV status Negative (n = 127) 68 (S3.S) 59 {46.S) 2.21 (1.35-3.61) 0.002 
Positive (n= 143) 
~~(32 . 3) 94 {6S.7) 
·······••¥" . ........... 
i '.69 (0.93--3.07) Retreatment No (n= 54) 29 (53 .7) 25 (46.3) 0.31 
... yes (~= ~~l:i) . ?8(:40.:7) . .. _12s L59.3} 
Drug resistance No (n= 219) 102 (46.6) 117 {S3.4) 2.09 (1.08-4.04) 0.03 
Yes (n = _51.) __ ~5__{ 29..4) 
.... 
36(?6.6) 
Days to sputum :5 6 days (n = 130) so {38.S) 80 (61.S) 0.61 {0.37-0.99) 0.05 
positivity - > 6 days (n = 136) 
culture 66_ (~_8.5[ 70 (Sl.S)_ 
-
AFB density at 0 (n = 23) 17 {73.9) 6 (26.1) 0.07 (0.01-0.3) <.0001 
baseline 
1+ (n = 22) 14 (63.6) 8 (36.4) 0.27 {0.10-0.69) 0.007 
2+ (n = 30) 15 (SO) 15 (SO) 0.47 (0.21-1.06) 0 .09 
3+ (n = 73) 32 (43.8) 41 (S6.2) 0.60 {0.33-1.1) 0.12 
4+ (~ = 122) 39 {32) 1 1 
Cavitary No (n = 85) 49 (S7.7) 2.54 {1.47-4.39) 0.001 
disease ~es (n = 149} . ?2(3':1::9) --
History of No(n = 175) 86 (49.1) 89 {50.9) 2 (1.18-3.36) 0.01 
smo_kin~ Yes (n = 96) 31 (32.6) 64 {67.4) 
....... ~ .... ............ ... 
Current alcohol No (n= 230) 100 {43.S) 130 (S6.S) 1.04 (0.53-2.05) 1 
consumption Yes (n= 40) 17 (42.S) 23 (S7.S) 
52 
Table 20. Logistic regression-derived Odds Ratio for volume category variable in 270 hospitalized TB 
patients in Kampala, Uganda by first spot sputum measurement. (Objective 2) 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio logistic Regression 
Model in model 
building procedure 
Volume 1.24 
Volume and cavitary 1.046 15.6% 1 
disease at baseline 
Volume and AFB smear 1.093 11.9% 2 
density 
Volume and HIV status 1.122 10.5% 3 
Volume and smoking 1.154 6.9% 4 
history 
Volume and drug 1.224 1.3% 5 
resistance 
Volume and days to 1.235 0.4% 6 
sputum positivity (in 
baseline liquid culture) 
53 
V1 
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Table 21. Multivariable association between two month sputum culture and baseline characteristics 270 hospitalized TB patients in 
Kampala, Uganda by first spot sputum measurement. (Objective 2} 
Model Factor Level AIC1 Adjusted OR2 C- Hosmer- Hosmer- Model % Change in Decision 
(95% C1)3 statistic Lemeshow Lemeshow p- p-value Adjusted OR 
test value 
1 I !v1o~~~---~ - ~~-~-=-~ .. 2?1:!L... ... --~--·----~---.. --.. 0 nl~~---~-~~-~-~~· -~-~~-~-"· - -~--·-·=·· --~~-- -
Volume ~ 3 ml 1.24 (0.7-2.03) 0.39 Category 
2 I Mod~--~--~~----~---~314:1_ ___ 0.62 ~_Q.86 __ ~----~-_ _ <!:_003 ____  ~-~--------~----~ 
Volume ~ 3 ml 0.90 (0.51-1.56) 0.70 
category 
··· C:ii~iia r(disease-- ~~:~~~t---~ · --~-- - ;-.;~ (~.~~~~ .;l- ----- ·· - · --- --- ·- -- -- -~- -· · -- ·- ·-~.~~~~--- -~- 27.8% 
at ase me · 
3 I Model 294 0.53 7.05 0.65 0.0009 
VOlume -
a. WiJ!"""f'7",. ~---- :-~·- -~·-----... -
~3 ml 0.69 (0.38-1.25) 0.22 
cate~ory __,.~~- ~-.=--~~~-. ..-..::....~~------_-......,._.c.._.;__...,_ ______ .....:__~---·-'-=-~---:.: ..... ..,;;....;_ .. ,--..:...-· -----~-·-~--..........__... I Cavitary disease 
at baseline Present 
2.71 (1.5-4.88) 0.0009 
oiiYSiOsJ)t:i"ium 
positivity (in 
< 6 days 0.95 (0.92-0.99) 23.3% 0.01 Keep in model baseline liquid 
culture) 
4 I Model 291.3 0.66 1.42 0.99 0.0003 
volume--c··----~--~-~----~-----~~-·-~--~-~-----.. --~---- .. - - ---,----- -~-----~--------------~=---~-- ----~-~--~---~-----~ .... -~-------- ----------------~-----~-------
~ 3 ml 0.69 (0.38-1.27) 0.24 Categorv~- _ 
. ..,. 
-........ _,..., ~ ................ -~---~--~------....-..-..~-~-=·~.-:...&--"'-"""' 
Cavitary disease Present 2.47 (1.36-4.5) 0.003 
at base line 
Days to sputum ·- ---...,--~- --- n --~ -
positivity (in 
< 6 days 0.97 (0.93-1.02) 0.21 
baseline liquid 
culture 
-------
Baseline 0% Remove f rom lncreme 1.32 (1.03-1.7) 0.03 sputum 
ntsof1+ model 
baci llary grade 
-5 I Model 
---- ----~~--.. ·---------
Volume ~ 3 ml 0.67 (0.37-1.23) 0.20 
U1 
U1 
category 
Cavitary disease 
Present 
at basel ine 2.3 (1.22-4.33) 0.01 
-' ·-
-· 
Days to sputum 
nnd ti\lih1 fin 
< 6 days 0.96 (0.92-0.99) 0.03 
~ 
______ .,...,..._. __ _ 
----· 
HIV status Infected 1.52 (0.83-2.79) 0.18 
- -6 1 Model 294.6 0.65 8.83 0.26 2.;2£1 
Volume ~3 ml 
categorv •. 
0.23 
............, ··-- · 
0.69 (0.38-1.27) 
Cavitary disease Present 
at baseline 
0.002 2.57 (1.42-4.67) 
Days to sputum 
. .. -~r,_,.,_ 
positivity (in 
< 6 days baseline liquid 0.95 (0.92-0.99) 0.02 
cu lture)_ 
I Resistan t to 1st 
Drug resistance or 2nd 1.52 (0.75-3 .08) 0.25 
line 
agent 
Final Model 
Volume 
category 
294 . 0.65 7.05 0.53 0.0009 
~--·--~--.. --- -~- ""-"-----------·"""""-·"·'_..._..._ .. --.. .. - . ...-...-... ~-~- ,. _ • ..:...~ ........... ~ .. _____ J~-.... ·---'"""-- ·......,__.......,;,,...,._, ______ ~ _ __ .. ________ .~ -----~- ---
2! 3 ml 
~Cavitary disease P t 
. resen 
. ~-t base~_E,: ___ , 
Days to sputum 
positivity (in 
baseline liquid 
culture) 
< 6 days 
1AIC =Aka ike's Information Criterion 
20R = Odds Ratio 
395% Cl = 95% Confidence Interval 
0.69 (0.38-1. 25) 0.22 
2.71 (1.5-4.88) 0.0009 
0.95 (0.92-0.99) 0.01 
2.9% 
0% 
Remove f rom 
model 
Remove from 
model 
.;...,~ ..... - ...J>..t. .. _,_,.,_, _ _ .._ __ ~ ....... , •• _____ ,,_;_,.,.,;,:.;.._,.,,, ""'-·---~-----1 
23.3% Keep in model 
Table 22. Bivariate association between two-month sputum culture and baseline characteristics in 273 
hospitalized TB patients in Kampala, Uganda according to early morning sputum volume status. {Objective 
2} 
Characteristic Level Negative AFB Positive AFB OR (95% Cl} p value 
culture culture 
(n = 124, (n = 167, 55.5%} 
44.5%} 
:volume category Low(< 3 ml; n = 102) 51 (SO) 51 (SO.) 1.76 (1.07-2.89) 0.03 
I High(~ 3mL; n= 171) I 
.... -
.. §2( 363). 109 (63.7) 
Age <30 (n = 102) 38 (37.3) 64 (62.7) 1.06 (0.54-2.12) 0.86 
1.57 (0.952.59) 
30-40 (n = 118) 58 (49.2) 60(50.8) 1 0.25 
>40 (n =53) 22 (41.5) 31 (58.5) 1 
Gender Female (n :: 97) 48 (49.5) 49 (50.5) 1.57 (0.95-2.59) 0 .13 
M_a 1.~ (n = 17§) 70{?~:?! ........... 196 (6Q.?) 
HIV status Negative (n = 128) 68 (53.1) 60 (46.9) 2.09 (1 .28-3.4) 0.002 
Positive (n = 145) so (34.5) 
"' 
... 
95 (65.52 
i Retreatment No (n = 43) 23 (53.5) 20 (46.5) 1.43 (0.74-2.75} 0 .18 
...... Y~~ ( n .': ?3.Q) . _ 
... ~-
95 J~1:}) 135 (58.7) 
-Drug resistance No (n = 219) 103 (47) 116 (53) 2.11 (1.1-4.04} 0.01 
Yes (n =54) 15 (27. 8.) 39 (72.2) 
Days to sputum $ 6 days (n = 142.) .... 51 (35.9) 91 (64.1) . 0.47 (0.35-0.94} 0.01 
positivity- category > 6 days (n = 131) 
67 (51) 
..... 
6~_(48 . 9) 
. --
AFB density at baseline 0 (n = 27) 22 (81.5) 5 (18.5) 0.07 (0.01-0.3) <.0001 
0.13 (0.03-0.65) 
1+(n=13) 8 (61.5) 5 (38.5) 0.22 (0.08-0.56) 
0.54 (0 .27-1.08) 0.008 
2+ (n = 34) 17 (SO) 17 (SO) 1 0.002 
3+ (n = 65) 25 (38.5) 40 (61.5) 0.09 
4+ (n =:. ~?) ~? (~8. - ~l .. §~ (7~ .§) ... 
! Cavitary disease No (n= 64) 42 (65.6) 22 (34.4) 3.2 (1.65-6.19) 
Y~s_(n:: 95). - ~7[!8.9 ) 
...... 
58 (61) 
~-- . 
History of smoking No(n = 181) 84 (46.4) 97 (53.6) 1.88 (1.11-3.2) 0.03 
Yes (n = 92) 29 (31.5) 
-
63 (68.5) 
Current alcohol No Tn; 237) 103 (43.5) 134 (56.5) 1.13 (0.55-2.31) 
' consumption Yes (n = 36) 15 (41.7) 21 (58.3) 
56 
Table 23 . Logistic regression-derived Odds Ratio for volume category variable in 273 hospitalized TB 
patients in Kampala, Uganda by first early morning sputum measurement. (Objective 2} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 1.76 
Volume and AFB smear 1.321 24.9% 1 
density at baseline 
Volume and cavitary 1.56 11.4% 2 
lesions at baseline 
Vo lume and HIV status 1.67 5.1% 3 
Volume and history of 1.69 4.1% 4 
smoking 
Volume and days to 1.773 0.74% 5 
sputum positivity (in 
baseline liquid culture) 
Volume and drug 1.75 0.57% 6 
resistance 
57 
lJ1 
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Table 24. Multivariable association between two month sputum culture and baseline characteristics in 273 hospitalized TB patients in 
Kampala, Uganda according to early morning sputum volume status. (Objective 2) 
Model 
1 
2 
3 
4 
5 
6 
Factor Level AIC1 
_!'!'_<:>del_~~~- -- __ 3_~9.4 
Volume Category :<: 3 ml 
Adjusted OR2 
(95% Cl)3 
-
1.76 (1.07-
2.89) 
(-
statistic 
__ 0.5? _ 
Hosmer- Hosmer- Model %Change in Decision 
Lemeshow test Lemeshow p- p- Adjusted OR 
value value 
0 n/a 
···- _().:..<:!~.-" _ .f)L~------
0.03 
I- ModE!I ~ 34:1,} -~~--~=~ _0.33 0.95 :::.0001 ~---- ___ . ---·-- ---
Volume category :<: 3 ml 1.32 (0.77-
2.26) 
Baseline sputum Increments 1.96 (1.49-
bacillary grade of 1+ 2.57) 
0.31 
<:o0ci1~25% Keep in 
model 
Model 120.5 0.75 1.43 0.96 <.0001 
_yol~me -cai:eg~rY ----=--~ 3_ iT;t:·-<·=----=~:~=~T.2((7f4~)l _. ~ .· -~~=:- ----~=~~ ~--:-:_-.=~.=.---··=·=:::__:o.68 -~-~~-~=-~ ---.=.:. ~~=~·~:=---~ 
Baseline sputum Increments 1.93 (1.24-3) 
bacillary grade of 1 + 
Cavit; ry disease 
337.8 0.71 1.05 
~3 ml 1.27 (0.74-
0.004 
0.054 
0.96 <.0001 
0.39 
8.3% Remove 
from model 
~···""- ·" ''~--.. .... .....:.. .. """'"····---- ............ .... --·. -'i........-..;.,;,;.; ........... ....... _.....,.1_.19) ______ ______ ~-~---------~--- ~ ... ;·'""'""'-·--..... - .. ... . .---~---~· J... ~...---· .............................. - ... - •• ·--·'·····"""··-.....;;,-·~· 
Baseline sputum Increments 1.93 (1.47-
bacillary grade of 1+ i-l 1v 5tatUS ____ _,rnre·cted 2.54) -----~l.:aG(l.i~-
1 
Model _ 340.7 
Volume category ~ 3 ml 
Increments 
of 1+ 
Positive 
:<:3 ml 
291.3 
3.13) 
1.29 (0.75-
2.22) __ 
1.92 (1.46-
2.520 
1.57 (0.9-
2.75) 
1.4 (0.78-
2.5?) 
<.0001 
0.02 3~8% ~-~- Re move-·· 
from model 
0.70 2.07 0.91 <.0001 
0.71 4.41 0.82 
0.36 
<.0001 
0.11 2.3% 
<.0001 
0.26 
Remove 
from model 
V1 
\.0 
Baseline sputum Increments 2.15 (1.53- <.0001 
bacilla ry ~rade of 1+ 3.03) < 6lavs" .,., ·- - ~ ~ "' -.1 .. ~--=--·--~--~,. -~~~"-o'"':n ·- --·--~~-Remove Days to sputum 0.99 (0.96- 8% 
positivity (in baseline 1.03) from model 
liquid culture} 
Final I Model 341.3 0.68 0.33 0.95 <.0001 
~3 mL (0:77= --
_______ _2-~L~---- ···'-- --- -·----~------------~---~-~----'---- ------ ------~ -----------~-- -~--~~--------
Baseline sputum Increments 
bacillary grade of 1+ 
1AIC = Akaike's Information Criterion 
20R = Odds Ratio 
395% Cl = 95% Confidence Interval 
1.96 (1.49- <.0001 25% Keep in 
2.57} model 
Table 25 . Bivariate association between two-month sputum culture and baseline characteristics in 127 
HIV-seropositive patients in Kampala, Uganda by first spot sputum measurement. {Objective 2} 
Characteristic Level Negative culture Positive OR (95% Cl) p 
(n =68; 53.5% culture value 
(n =59; 
46.5%) 
Volume category Low(< 3 ml; n = 57) 33 (57.9) 24 (42.1) 1.38 (0.68-2.78) 0.47 
High (~ 3.m_L; I!=: 70) 35_(50) 
-
3? {!)0) 
... 
Age <30 (n = 27) 15 (55.6) 12 (44.4) 1.16 (0.37-3 .61) 1 
2.19 (0.84-5 .74) 
30-40 (n = 78) 31 (39.7) 47 (60.3) 1 0.14 
>40 (n = 22) 13 (59.1). 9 (40.9) 1 
·--· 
... 
Gender Female (n = 60) 35 (58.3) 25 (41.7) 1.44 (0.71-2.91) 0.37 
1\ll. a. l ~ (~ :: 6?) 33(~9.?) 
.. .. .......... -
__ ,_}~ (?.0. 7) 
... 
Retreatment No (n= 37) 25 (67.6) 12 (32.4) 2.28 (1.02-5.08) 0.051 
Yes (n= 90) ~? (~7. ~l_ 47 (52.2) 
Drug resistance No (n= 110) 62 (56.4) 48 (43.6) 2.37 (0.82-6.86) 0.12 
y~s(n= g)_ 6 (35}) . 1 ~ (6~:7) ····· 
Days to sputum ~ 6 days (n = 58) 28 (48.3) 30 (51.7) 0.69 (0.34-1.4) 0.37 
positivity -
culture >_f? days(n = 6.8) 
······ ... ?9(.5.?:~) .. 2~ (42.?) .. . 
. .... 
AFB density at 0 (n = 15) ll (73.3) 4 (26.7) 0.26 (0.07-0.94) 0.05 
baseline 0.37 (0.1-1.39) 
1+ (n = 12) 8 (66.7) 4 (33.3) 0.97 (0.34-2.78) 0.2 
2+ (n = 21) 9 (42.9) 12 (57.1) 0.45 (0.18-1.12) 1 1 
3+(n=34) 21 (61.8) 13 (38.2) 0.11 
4+ (n = 35) 19 (54.3L 2§ (?4.3) 1 
Duration of TB < 12 weeks (n = 91) 37 (40.7) 54 (59.3) 0.44 (0.2-0.96) 0.05 
symptoms ~ 12 weeks (n = 36) 
22, (61.1) 14 (38.9) 
Cavitary disease No (n = 62) 38 (61.3) 24 (38.7) 2.2 (0.99-4.86) 
~"'" .... )'es(n = .4.?) .... . . . .. . .~ .. 8 ( '!..!: .. ~l 25 58.1 . .. 
History of No(n = 85) 51 (60) 34 (40) 2.21 (1.04-4.69) 0.06 
smoking Yes (n = 42) 
____ 17_(~0:~) 25 (59.5) 
Current alcohol No (n= 19) 9 (47.4) 10 (52.6) 0.75 (0.29-1.99) 0.62 
consumption Yes (n= 108) 59 (54.6) 49 (45.4) 
60 
Table 26. Logistic regression-derived Odds Ratio for volume category variable in 127 HIV-seropositive 
patients in Kampala, Uganda by first spot sputum measurement. {Objective 2} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 1.375 
Volume and cavitary 1.173 26% 1 
lesions at baseline 
Volume and history of 1.173 14.7% 2 
smoking 
Volume and retreatment 1.275 7.3% 3 
status 
Volume and duration of 1.366 0.65% 4 
TB symptoms 
61 
Table 27. Multivariable association between two-month sputum culture and baseline characteristics in 127 HIV-seropositive subjects 
with baseline spot samples (n = 127}. (Objective 2) 
Model Factor Level AIC1 Adjusted OR2 C- Hosmer- Hosme Model %Change Decision 
(95% Cl)3 statis Lemeshow r- p-value in 
tic . test · Lemes Adjusted 
how p- OR 
value 
1 I Model ._ _ _ .17~:L~~ ~~-~ _ _______Q .54_ 0 ___ ~  0.38 -----~-----
Volume ;;:: 3 ml 1.38 (068-2.78} 0.38 
Category 
2 I ,Mogel .-~~----· --~~-- 147.2 ---~=·~~----~· -~-~0.60 ~0.96 _ ~--- --_Q:Q? ___ _Q~ 14~_ ----~-~-~---~ 
Volume ;;:: 3 ml 1.02 (0.5-2.26} 0.97 
category 
cavitary ·--~~- ··Prese nt' -~-~-~ 2.19 (6.98-4.19} 0.06 26% Keep in 
~ I disease at model 
baseline 
3 I Model -~----~-!~~ ~-~~~~~-£:~-2---~3 0.99 ~-~·03 
;;:: 3 ml 0.82 (0.35-1.9} · 0.63 
~~-~---~--------~·-----....;;........ .• _ ................ 
Present 2.07 (0.91-4.72} 0.08 
disease at 
baseline 
smoklng -- ~ Present~2.7G (1.n1-6.89) 0.03 19.6% Keep in 
history model 
4 I Model 144 0.68 1.67 0.95 0.03 
volume-~mL - D.7'6"(D.32--1.~~----- ---~--- 0 .53 
Categg_ry 
Cavitary Present 1.9(0.82-4.39) 0.14 
disease at 
baseline 
Smoking Present 2.8 (1.11-7.1) 0.03 
r i ~.!.o rv. _ ___ _.... ________ __ _____ ..... ··-·---~ _____ , .. _____ , _, __ ___.-'---· ··· ·-- ___ .,_ ........... ......._.. _____ 
---·-- --
Retreatment Positive 1.96 (0.81-4.74) 0.13 7.3% Remove 
status from 
model 
5 I Model 144.2 0.68 0.99 0.60 0.03 
-- ~-..:...__.... ___ ......._- -~--~~---~-~--_......;....__ . ....:.. ..• -~· --~- . .-..::c.•-----~------·-· __ .... ··~· -~ ........ ---~·--
Volume ;::: 3 mL 0.82 (0.35-1.92) 0.65 
~a~go:y_ _ ~~ _ 
-~----- ----n-Cavitary Present 2.11 (0.92-4.88) 0.08 
disease at 
baseline 
--· 
-·~~ --~ ......__-----~-~-.- ---- - ·-~· -~~~-~~--
" Smoking Present 2.63 (1.04-6 .65) 0.04 
history 
---- - -· ---~~,..,..._ .. __ , _ 
Duration of TB ;:::12 0.41 (0.16-1.03) 0.2 0% Remove 
symptoms weeks from 
0"1 I Model model w Final 144.3 0.66 0.99 0.13 0.03 0.99 
Volume ;:::3 ml 0.82 (0.35-1.9) 0.63 
category 
Cavitary Present 2.07 (0.91-4.72) 0.08 
disease at 
baseline 
----~-----Smoking Present 2.76 (1.1-6.89) 0.03 
history 
1AIC =Aka ike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
Table 28 . Bivariate association between two month sputum culture and baseline characteristics in 143 
HIV-seronegative patients in Kampala, Uganda by first spot sputum measurement. (Objective 2} 
Characteristic 
Volume category 
Age 
Gender 
Retreatment 
Drug resistance 
Days to sputum 
positivity-
culture 
AFB density at 
baseline 
Duration of TB 
syf!lptoms _ 
Cavitary disease 
History of 
smoking 
Current alcohol 
consumption 
Level 
Low ( < 3 m L; n = 46) 
High(<: 3ml; .n = 97) 
<30 (n = 73) 
30-40 (n = 42) 
>49 (n_= 2?)_ 
Female (n = 37) 
IIJlale (n = 106) 
No (n= 17) 
Yes (n= 126) 
No (n= 109) 
_Yes (n_= 34) ....... __ 
::; 6 days (n = 72) 
> 6 days (n = 68) 
0 (n = 8) 
1+ (n = 10) 
2+ (n = 9) 
3+ (n = 39) 
4+ (n = 7?) 
< 12 weeks (n = 79) 
~. ~2 weeks_(n =:= 64~ . 
No (n = 23) 
. Yes (n = ~00) 
No(n = 90) 
Yes (n =53) 
No (n= 21) 
Yes (n= 122) 
Negative 
culture 
(n =49; 
34.3%) 
Positive culture 
(n = 94; 65.7%) 
15 (32.6) 31 (67.4) 
34 (~ 5.~) ~3 (64.9) 
28 (38.4) 45 (61.6) 
11 (26.2) 31 (73.8) 
10 (35.7) 18 (64.3) 
13 (35.1) 24 (64.9) 
}§ @.~) 70 (6§:6) . 
4 (23.5) 13 (76.5) 
45 (35.7) 81 (64.3) 
. . 
40 (36.7) 69 (63.3) 
9_(26.5) ................. 25(73.5) 
22 (30.6) so (69.4) 
27 (39.7) 
6 (75) 
6 (60) 
6 (66.7) 
11 (28.2) 
?O (26J 
37 (46.8) 
12 (~8:?) 
11 (47.8) 
. -~4 (34) 
35 (38.9) 
1i (26._~) 
8 (38.1) 
41 (33.6) 
64 
41 (60.3) 
2 (25) 
4 {40) 
3 {33.3) 
28 (71.8) 
57 (74) 
42 (53.2) 
S?J8~: 2) 
12 (52.2) 
72(!2) -
55 (61.1) 
_?9 (73.6) 
13 (61.9) 
81 {66.4) 
OR (95% Cl) 
0.9(0.43-1.89) 
0.89 (0.36-2.21) 
1.57 (0.56-4.41) 
1 
1.05 (0.48-2.31) 
········-····· · -··-·· 
0.55 (0.17-1.8) 
1.61 (0.68-3.79) 
0.67 (0.33-1.34) 
0.12(0.02-0.63) 
0.23 (0.06-0.91) 
0.17 {0.04-0.77) 
0.89 (0.38-2.12) 
1 
3.82 (1.78-8.23) 
1.94 (0.78-4.84) 
1.78 (0.84-3 .73) 
1.22 (0.47-3.17) 
p value 
0.85 
1 
0.43 
1 
1 
0.42 
0.29 
0.009 
0.05 
0.02 
0.83 
1 
0.04 
0.16 
0.15 
0.80 
Table 29. Logistic regression-derived Odds Ratio for volume category variable in 143 HIV-seronegative 
patients in Kampala, Uganda by first spot sputum measurement. {Objective 2} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio logistic Regression 
Model in model 
building procedure 
Volume 0.897 
Volume and duration of 1.121 25% 1 
TB symptoms 
Volume and baseline AFB 0.855 4.7% 2 
density 
65 
(j) 
(j) 
Table 30. Multivariable association between positive two-month sputum culture outcome and baseline characteristics in 143 HIV-
seronegative subjects with baseline spot sputum samples. (Objective 2) 
Model Factor 
1 Mo~! 
Volume 
Catel!or 
Level AICl 
187.8 
........_.~ ............. --
::::3 mL 
2 _Mgdel 
Volume 
. ---··-~ . .!tl~ :1~ --
::::3 mL 
3 
category 
Duratfoii" of :::: 12 
TB weeks 
symptoms 
Final I Model 
Volume 
svmotoms 
~ 12 
weeks 
1AIC = Akaike's Information Criterion 
20R = Odds Ratio 
395% Cl = 95% Confidence Interval 
C- Hosmer- Hosmer-
statistic Lemeshow Lemeshow 
test p-value 
Model % Decision 
p-value Change in 
Adjusted 
OR 
_______ _Q_~1_ ____ Q__ _________ ~ ___ I1L~~--""-·J!:TL~ ~ 
0.90 (0.43-
1.89 
-=-------~--~-- ~ -- -~---·----- .Q ~§.§ __ _ 
1.12 (0.51-
2.45) 
roci={o6) 
__Q~Q;i.~·--~-- _Q~-2~---· 
0.77 
~04 
0.78 
0.04 25% Keep in 
model 
0.75 7.02 032 ~----~-- 0.0004 ---·o 89 ______________ , ________________ ·--· 
1.12 (0.51-
2.45 
1.0(1-1.06) 
----~- .. .____._ .. ------~-
0.66 0.03 0.98 
0.06 
0.001 
, y. - -.---.....-~ ..... -----~--· 
5.4% Remove 
from 
model 
0.04 
0.78 -~-~-----1 
0.04 
Table 31. Bivariate association between two-month sputum culture outcome and baseline characteri stics 
in 128 HIV-seropositive patients in Kampala, Uganda by first early morning sputum measurement. 
(Objective 2} 
Characteristic Level Negative Positive OR (95% Cl) p value 
culture culture 
(n =65; (n = 63; 
50.8%) 49.2%) 
Volume category Low(< 3 ml; n = 54) 32 (59.3) 22 (40.7) 1.81 (0.89-3.68) 0.11 
..... High(~ ?mL; n = 7~) .... . 3.3 (~4.6) 4~- (S_?_:~L .... 
Age <30 (n = 29) 11 (37.9) 18 (62.1) 1.17 (0 .39-3.53) 1 
30-40 (n = 75) 31 (41.3) 35 (46.7) 0.5 (0.2-1.28) 0.16 1 
>40(n= 24) 10 (41.7) 
.... }~ (!)~.3) 1 
" .. ............... ......... 
Gender Female (n = 62) 34 (54.8) 28 (45.2) 1.37 (0.68-2.75) 0.38 
Male (f1 = 66} 31 (47) 
_} ? (??l 
Retreatment No (n= 26) 17 (65.4) 9 (34.6) 2.13 (0.87-5.21) 0.13 
Yes(n= 192)_ ... 48._ (4!) __ 54 (53) 
Drug resistance No (n= 109) 59 (54.1) 50 (45.9) 2.56 (0.94-5.65) 0.08 
... / 
_Yes (n = 19) 6 (31.€) 13 (68:4) 
-
Days to sputum $ 6 days (n = 69) 29 (42) 40 (58) 0.46 (0.23-0.94) 0.04 
positivity -
culture > 6 <;J_ays (n == ~~) 36 (§ll 23 (39) 
AFB density at 0 (n = 11) 9 (81.8) 2 (18.2) 0.16 (0.03-0.77) 0.02 
baseline 
1+ (n = 4) 3 (75) 1 (25) 0.24 (0.02-2.37) 0.31 
2+ (n = 14) 10 (71.4) 4 (28.6) 0.28 (0.08-0.98) 0.05 
3+(n=17) 9 (52.9) 8 (47.1) 0.63 (0.22·1.8) 0.43 
4+ (n = 82) 34 (41.5) 48 (58.5) 1 1 
····-··. 
A-••• • 
Duration of TB < 12 weeks (n = 102) 56 (54.9) 46 (45.1) 2.3 (0.94-5.65) 0.08 
___ symptoms 
..... <:12w~e~sJn:= ?.6.). 9(3~·?L ....... 17 (65.4) ............................ 
Cavitary disease No (n =46) 31 (67.4) 15 (32.6) 3.34 {1.33-8.43) 0.01 
Yes (n = 34) 13 (54.2) 21 (6!.8) 
History of No(n = 90) 49 (54.4) 41 (45.6) 1.65 (0.76-3.54) 0.25 
sr:nokin~ .  Yes (n = 38) ... ~? (:72:_1) 22 (57.9) 
... 
Current alcohol No (n= 17) 8 (47.1) 9 (52.9) 0.84 (0.30-2.34) 0.80 
consumption Yes (n= 111) 57 (51.4) 54 (48.6) 
67 
Table 32 . Logistic regression-derived Odds Ratio for volume category variable in 128 H IV-seropositive 
patients in Kampala, Uganda by first early morning sputum measurement. (Objective 2} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 1.807 
Volume and baseline AFB 1.382 23.5% 1 
density 
Volume and days to 1.673 7.4% 2 
sputum culture positivity 
Volume and duration of 1.896 4.9% 3 
TB symptoms 
Volume and drug 1.73 4.3% 4 
resistance 
Volume and baseline 1.875 3.8% 5 
cavitary disease 
68 
(]) 
1.0 
Table 33. Multivariable association between positive two-month sputum culture and baseline characteristics in HIV-seropositive subjects 
with baseline early morning sputum samples (n = 128}. {Objective 2} 
Model 
1 
2 
3 
4 
5 
Final 
Factor Level AIC1 Adjusted ORZ C- Hosmer-
(95% Cl)3 statistic Lemeshow 
test 
Hosmer-
Lemesho 
wp-
value 
Model 
p-value 
0.10 
%Change 
in 
Adjusted 
OR 
_  ,. ____ _Q:_Q03 __ ~ 
___ ......._. __ _-s, 
qensi 
;:-:3 mL increments '()£ i+ 1.38 (0.65-2.94) L6(i:i4-2.ZS) 
Model 172.1 0.66 
y_il_l!:!_~ca~2::rY= ~_E_i!ii_ -C-=-== -:-~==--T~~-(Q_&fz::?~j_ __ 
Baseline AFB Increments of 1 + 1.52 (1.09-2.13) 
0.82 
169.5 0.68 5.33 
0.40 
-~o1Jo6 
0.84 0.004 
-·~~- "" _ _::::::::_()As _ 
0.01 
0.16 
0.38 0.001 
-23.5% 
2.9% 
·- · --~_:f4"UQ.67 :f'!1[~==:~ -=:_:·:::_- '-- = -• .·· <1f?_=~::===:_' 
1.65 (1.17-2.33) 0.005 
0.04 4.3% 
172.4 0.66 0.90 0.97 0.005 
----~~ 
- ~-_ . __ _ -·· - --~
-·-· --····---··-·· -~---------. ~.-Increments of1+ 1.56 (1.11-2.19) 0.01 
de~~ty~--
Resistant to 1st" """ - 1.97 (0.68-5.69) Drug resistance 1.5% 0.21 
or 2nd line aient 
Model 105.8 0.72 3.19 0.87 0.006 
--- ---------- --- ----·- - -- ----- - -- -- --·- ---- 0.3_§ 
0.07 
Decision 
Keep in 
model 
Remove 
from model 
Remove 
from model 
-....! 
0 
l_~t ba~eline 
1AIC =Aka ike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
~<-~< _n:!_<>_chl_ , __ =_ l 
Table 34. Bivariate association between two-month sputum culture outcome and baseline characteristics 
in 145 HIV-seronegative patients in Kampala, Uganda by first early morning sputum measurement. 
(Objective 2} 
Characteristic Level 
Volume category Low(< 3 mL; n = 48) 
High(~ 3ml; n = 97) 
Age <30 (n = 73) 
30-40 (n = 43) 
>40 (11_ = 29)_ ' 
. Gender Male (n = llb) 
Female (n = 35) 
Negative Positive 
culture culture 
(n = 48; (n = 97; 
33.1%} 66.9%} 
19 {39.6) 29 {60.4) 
26 (26.8) . 68(70.1) 
26 {35.6) 47 {64.4) 
12 (27.9) 31 {71.1) 
10 {34.5) •·w•••· - ~-~ ( §? :Sl ... ................................. 
35 (31.8) 75 (68.2) 
....... . .... ! 3 (37.1) .... . ?2(6.?~ _9) _ 
Retreatment 
Drug resistance 
Days to sputum 
positivity-
culture 
No (n= 17) 
YesJ~=:= .. 1?.?J 
No (n= 110) 
Yes (n_:= 35l 
~ 6 days (n = 79) 
4 {23.5) 13 (76.5) 
~~J?~:~l ----- ~_(6~ .6) 
39 (35.5) 71 {64.5) 
9 (25 ._7) 2§(74.:3) . 
23 (29.1) 56 {70.9) 
OR (95% Cl} 
1.54 (0.75-
3.17) 
0.95 (0.39-2.35) 
1.36 (0.49-3.75) 
1 
1.27 (0.57-2.8) 
0.59 {0.18-
_ 1_:~~)_ ____ _ 
1.59 {0.68-3.7) 
0.67 (0.34-
1.35) 
AFB density at 
. baseline 
..... > § ~~y~Jil ~ §_§)_ 
0 (n = 5) 
........... ~? (??· ~L. .. --- ~!J§?·~l.. .., ..... 
5 (1ooJ o (OJ a· 
1+ (n = 5) 4 {80) 1 (20) 0.08 (0.008-0.73) 
2+ (n = 8) 5 (62.5) 3 (37.5) 0.19 (0.04-0.84) 
3+ (n = 22) 9 (40.9) 13 (59.1) 0.45 (0.17-1.18) 
... . .... __ ..... 4:1' (JJ:=)05) . .. • _2~_(23.: 8) . ___ ?.o (7§.2L. 
Duration ofTB < 12 weeks (n = 76) 38 (39.6) 58 {60.4) 2.56 (1.14-
. sy111ptom ... .... s ...... ........................................ ~ ..... ... 1 ...? .""..f!~ ~s (11 : ~~) .... }_0, (?0_:~) ..... ?.9<7.~.:.6) .,, ... . 5.7?)_ 
Cavitary disease No (n = 18) 10 (55,6) 8 {44.4) 2.38 (0.82-
p value 
0.26 
0.61 
1 
1 
0.68 
0.43 
0.31 
0.29 
0.02 
0.03 
0.12 
1 
0.03 
_,.,, A. 
. yes (n ::: §~L . _ ?_1j3_~:.~L 4()( §5.(5) .... ?.:94} ... ------
History of No{n = 91) 35 {38.5) 
Yes (n =54) 13 {24.1) 
N() (;:;,; i 9) 6 (31.6) 5111_? ki_ll.~ : Current alcohol 
consumption Yes (n= 126) 42 (33.6) 
71 
56 {61.5) 1.97 (0.93- 0.10 
... ~~ E? :.~! ...... - ~: 1~)- --··---··.--.. -· 
13 (68.4) 
84 (66.6) 
0.92 (0.33-2.6) 
Table 35. Logistic regression-derived Odds Ratio for volume category variable in 145 HIV-seronegative 
patients in Kampala, Uganda by first early morning sputum measurement. 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 1.536 
Volume and baseline AFB 1.201 21.8% 1 
density 
Volume and duration of 1.827 18.9% 2 
TB symptoms 
72 
-...J 
w 
Table 36. Multivariable association between positive two-month sputum culture outcome and baseline characteristics in HIV-
seronegative subjects with baseline early morning sputum samples (n = 145). {Objective 2} 
Model Factor Level AJCl 
1 !Model ~-~· ~- 186.8 
Volume ~ 3 mL 
Catee:ory 
2 _Mog~~--~·~~ ~~~··-~---~-~~67,3 
Volume ;:::3 mL 
~at~g2,!:y_·-··=- ~­
Baseline Increments 
AFB density of 1 + 
Adjusted QRZ 
(95% CJ)3 
1.54 (0.75-3.17) 
.. 
1.2 (0.54-2.68) 
2.5 (1.58: 3.93) 
C- Hosmer- Hosmer- Model %Change in 
statistic Lemeshow Lemeshow p-value Adjusted OR 
test p-value 
0.55 0 · . t-UA 0.25 
·- --~--
0.25 
0.69 0.26 __ ~-- 0.88 -- ·- --~~~.00!.~= 
0.65 
<.0001 22% 
Final I Model 
Volum;-·-~ 
162.5 0.73 0.48 <.0001 
-~~- -~- ill co.6I~.39) ;;::3mL 
1-c~~----'----· ··--- ~--~· ·-·-·--~---
. Increments 2.57 (1.62-4.1) 
of1+ 
~zweek5~~-- ~·· 3.21 (1:27 -s:Ti) 
1AIC =Aka ike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
~..-.r..·-·-
0.37 
<.0001 
0.02 
Decision 
Keep in 
model 
Table 37. Bivariate association between pulmonary TB treatment outcome (by sputum culture) and 
baseline characteristics in 196 TB patients in Kampala, Uganda by first spot sputum measurement. 
(Objective 3) 
Characteristic Level Successful Unsuccessful Odds Ratio p value 
outcome outcome (n= 51) (95%CI} 
(n=145} 1 
Gender Female (n = 66) 52 (78.8) 14 (21.2) 1.48 (0. 73-2.98) 0.31 
Male (t:J_= 130) 9:3 (?1.5) 37 (28.?) .. 
Age group <30 (n = 71) 57 (80.3) 14 (19.7) 0.37 (0.16-0.87)' 0.03 
30-40 (n = 85) 64 (75.3) 21 (24.7) 0.49 (0.22-1.1) 0.1 
>40 (J1 =~0) .?4 (60) . ~6(40) 1 1 
HIV status Infected (n = 91) 69 (75.8) 22 (24.2) 1.2 (0.63-2.28) 0.63 
.. ~ninf~cted. (n = lOS.) .. 
... 
7§J7?-~l ___ .. 29 (27.6) 
Retreatment No (n = 44) 33 (75) 11 (25) 1.07 (0.50-2 .32) 1 
TB Yes (n = 152) . ~12. (73.7) 4g_(?6.3) 
Drug N~ resista-~ce-(n = 1G2) 129 (79.6) 33 (20.4) 4.4 (2 .02-9.54) 0.0002 
Resistance 
__ Resistance (n :=. :?4L ... 2?. (79_.4) 1~ __ (5?.9) 
··--·-· 
-
Smoke history Never smoked (n = 121) 95 (78.5) 26 (21.5) 1.83 (0.96-3.49) 0.09 
-· 
Ever sm()ked (n :7?) ___ 
... 
50_(66.7) ~5 (33..3) 
Volume < 3 ml (n = 148) 115 (77.8) 33 (22.3) 2.09 (0.98-4.21) 0.06 
category ~ 3 ml (n =:= 48J 30 (62.5) 18 (37.5) 
Cavitary Absent (n = 64) 54 (84.4) 10 (15.6) 2.43 {1.13-5.25) 0.02 
lesions at Present (n = 132) 91 (68.9) 41 (31.1) 
baseline 
··- --· ····- ····- ···-
· AFB density at 0 (n = 14) 10 (71.4) 4 (28.6) 1.04 (0.3-3.59) 1 
baseline 
1+(n=15) 13 (86.7) 2 (13.3) 0.34 
0.4 (0.08-1.89) 
2+ (n = 22) 17 (77.3) 5 (22.7) 0.8 
3+ (n = 48) 35 (72.9) 13 (27.1) 
0. 76 (0.26-2.27) 
1 
4+ (n = 97) 70 (72.2) 27 (27.8) 0.96 (0.44-2.09) 1 
1 
... -
-·-
Post- No (171) 133 (78) 38 (22) 3. 79 (1.6-9) 0.003 
Secondary 
School Yes (25) 12 (48) 13 (52) 
Education 
-·· Duration of TB < 12 weeks (n = 139} 109 (78.4) 30 (21.6) 2.12 (1.08-4.15) 0.03 
symptoms ~ 12 weeks (n =57) 36 (63.2) 21 (36.8) 
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Table 38 . Logistic regression-derived Odds Ratio for volume category variable in 196 pulmonary TB 
patients in Kampala, Uganda by first spot sputum measurement. (Objective 3) 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 2.09 
Volume and cavitary 3.063 46.6% 1 
lesions 
Volume and drug 2.27 8.8% 2 
resistance 
Volume and post- 2.192 4.9% 3 
secondary school 
education 
Volume and age group 2.178 4.2% 
Volume and smoking 2.028 3% 4 
history 
Volume and duration of 2.04 2.4% 5 
TB symptoms 
Volume and HIV status 2.062 1.3% 6 
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Table 39. Multivariable association between unsuccessful pulmonary TB treatment outcome and baseline characteristics in 196 subjects 
with baseline spot samples . (Objective 3} 
Model Factor Level AICl Adjusted C- Hosmer- Hosmer- Model % Change in Decision 
ORZ (95% statistic Lemeshow Lemeshow p- p- Adjusted OR 
CI)3 test value value 
1 I ~~.:_!._ -~- -~- - M-·~---_ 24?:~- ___ c ___q:~_?_ _____ o - ---- --· ____ __ ?[~-~~- --~---- -~-_ 0.47 
Volume ~ 3 mL 1.28 (0.67- 0.47 
2.47 
2 I Model 73.7 0.63 0.65 -- 0.72 0.19 
-~· ~--··--·-"""'·---- ··•··•,__-!.. - -•·-·-·-··•·----~ •• '"··••---~---......__~.---- ,,,,,.C-~---~•-···•~--- ~- -···· ··--'--' '"_.._.._ __ , ~-- -·•· •·-· --- -~·-•• •-.._·--~-- -~ ..... __.___ , , , ~-. ..... --··-~---·-'· 
Volume ~ 3 mL 3.06 (0.89- 0.07 
category _ _ ____ _ __ _ 10.49) 
c avitaiy leSi'onspresenT --·~---~--- ~2.oT(o.3-3-:-85) -0.92- 46.4% Keep in 
at baseline model 
3 I Model 75.7 0.63 0.65 0.96 0.34 0.96 
Volume -~ 3~C -~~- -.-~ #~2.99 (0".84-- . ~--· --- ·----, ,,,..,, ~-,-- -- -- -·· ·-----·-~- -"~-0~09 
category~--- l~~L __ ----~--"-~~----~----- ______ _ 
-.J 1 Cavitary lesions present 1.08 (0.3-3.93) 0.90 
m at baseline 
Drugresistance "R.'eSSSta"iit to 1st .0.89 (0.19- 0.88 2~4% Remove 
or 2nd line 4.08) from model 
agent 
4 I Model 67.3 0.75 5.1 0.16 0.008 0.16 
4.03 (1~04--~ ~~-.. ~~ - 0.64 
15.951~-~"=- -- -- - ------ -------
0.943 (0.24-
3.76) 
Yes il.73-(1.91- 2.4% 0.008 Keep in 
72.12) model 
education 
5 I Model 69.2 0.75 1.69 0.95 0.02 
Volume ~ 3 mL 4.08 (1.05- 0.04 
category 15.92 
Cavitary lesions present 0.94 (0.24- 0.93 
at baseline 3. 7 6) 
Post-secondary Yes 12.09 (1.92- 0.008 
school 76.19 
-..J 
-..J 
6 
7 
education 
Age group >40 
Model 
Volume <: 3 mL 
category 
Cavlta~ry lesions present 
1.12 (0.48-
2.62) 
68:1_ __ _ 
4.02 (1.02-
15.9) 
-- -o.8 6(0.21-
0.77 __ 1.32 ~-~~---~--
.,. _______ - ~~--
~tEaselj~ -~---~ 
Post-secondary Yes 
--- ---~4-~.J...1~L-..... - ... ~-
school 
~ ~~----" Smoking history positive 
14.12 (2.14-
99.32) 
2:08 (0:55-
7.89) 
1 Model _ 61.4 ~---Volume <: 3 mL 5.76 (1.6-
0.84 2.24 0 81 
- -~--
0.79 1.2% 
0 .01=---~--
0.05 
0.83 
Remove 
from model 
--
__ __..__._........_ _____ -----..;_, _ ___.. _____ __ _ _ ····-··--" _;.....___. ___ ............,_ 
0.006 
0.28 
0.0006 
0.03 
0.2% -- ·Remove_.,.. 
from model 
cat~_go!JI: _ _ _ ~_ -~-- -·--- -----~-~2.B.5:n __ ----···-- - - - ------- -~~-~ -- - - - --"~----"-.. ~- -·~----~·~~~--- ----------- --- ~------- --- ---"'"""----"-·· ·· ·-~~---'-··-- --··---""'-.. . .:-.c .. .... . .:..-;..,,, ______ ,_.,__ 
8 
Cavitary lesions present 
at baseline 
POst~secolliiari ·~-ye;-
school 
1 education . __ _ Duration ofTB <: 12 weeks 
SYIJlptoms 
Model 
Volume <: 3 mL 
catElgory 
Cavitary lesions present 
at baseline 
Post-secondary Yes 
school 
education 
Duration ofTB ~ 12 weeks 
~_toms 
HIV status Infected 
63.3 
0.57 (0.13-
2.57) 
"" "'2ili3(2A9-" "' -----------------~- ____________ .. ______ _ 
177.55) 
8.07 (1.69-
38.59) 
6.09 (1.13-
32.9) 
0.6 (0.13-2.82) 
20.58 (2.42-
175) 
8.14 (1.69-
39.12) 
0.84 (0.18-4) 
·=· -----"-- '""''""--~"·•- .. 
0.84 2.92 0.82 
Final I Model • • 61.4 -~ 0.84 2.24 _ 0.81 
Volume <: 3 mL 5.76 (1.6-
category 28.53) 
CavitarilesiOns present ..Q.5U 0.13-~~-- ~~-
0.46 
- o:oos· 
0.009 43.3% 
0.001 
0.04 
0.51 
0.006 
0.009 
0.83 5.7% 
Keep in 
model 
Remove 
from model 
Q.0006 ~- ---1 
0.03 
OA6 
-....! 
00 
~L~~selin~-'"---~~­
Post-secondary Yes 
school 
education 
Dura tion of TB ""' ~12 weeks 
SY!!!Qtoms 
1AIC =Aka ike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
-~ ----~021 - ··- -
21.03 (2.49-
177.55) 
8.07 (1:69-
~~L 
0.005 
0.009 
Table 40. Bivariate association between pulmonary TB treatment outcome (by sputum culture) and 
baseline characteristics in 221 TB patients in Kampala, Uganda by first early morning sputum 
measurement. (Objective 3) 
Characteristic Level Successful Unsuccessful Odds Ratio p value 
outcome outcome (n= 54) (95%CI) 
(n=167) 
Gender Female (n = 73) 60 {82.2) 13 (17.8) 1.77 (0.8-3.56) 0.13 
Ma~eJn.:= 148) .19? (n3) 41.J27.?l . 
Age group <30 (n = 80) 64 {80) 13 {20) 0.47 (0 .21-1.06) 0.09 
30-40 (n = 95) 73 {76.8) 22 {23.2) 0.57 (0 .26-1.22) 0.16 1 
>4Q(n= 46) 
........ 30 {~? - 2) 16(?4.8) 1 
HIV status Infected (n = 82 {79.6) 21 {20.4) 1.47 (0.8-2.76) 0.27 
103) 
Uninfected (n = 85 {72.7) 32 {27.3) 
117) _ 
~~~--
"" 
... ,_ 
Retreatment TB No (n = 42) 30 {71.4) 12 {28.6) 0.77 (0.36-1.63) 0.55 
.. 
yes (~ ~ __ 179) 
........ ~3?(76:_?.) 42 {23.5) 
Drug Resistance No resistance (n 150 {82) 33 {18) 5.62 (2.67-11.8) <.0001 
= 183) 
Resistance (n = 17 {44.7) 21 {55.3) 
3.8) 
... 
-· .. 
-· 
Smoke history Never smoked 108 {79.4) 28 {20.6) 1.7 (0.91-3.16) 0.11 
(n = 136) 
Ever smoked (n 59 {69.4) 26 {30.6) 
= 85) 
.. 
Volume category < 3 ml (n = 156) 120 {76.9) 36 (23.1) 1.28 (0.66-2.47) 0.50 
<:} ml (n= 65) 47 {72.3) }8 {27:1~ 
Cavitary lesions Absent (n = 46) 39 {84.8) 7 {15.2) 2.6 (1.22-5.53) 0.04 
at baseline Pr._ese~_t ( ~ = 78) 52 {66.7) 26j 33_:3) 
, AFB density at 0 (n = 8) 8 {100) 0 {O) N/A 0.11 
baseline 
1+(n=9) 8 {88.9) 1 {11.1) 0.3 (0.04-2.42) 0.45 
0.25 (0.05-1.11) 0.07 2+ (n = 21) 19 {90.5) 2 {9.5) 
3+ (n = 32) 26 (81.3) 6 (18.7) 1.84 (0. 71-4. 78) 0.28 
4+ (n = 1?1)_ 106 {70.2) .... ~s (29.8) 1 1 
··-· 
Post-Secondary No {192) 149 (77.6) 42 (21.9) 2.52 (1.12-5.69) 0.04 
School Education 
Yes (?~l ... _17(?.~-6) __ 12~4~.4) 
Duration of TB < 12 weeks (n = 132 (78.1) 32 {18.9) 2.6 (1.34-5) 0.007 
symptoms 164) 
;:: 12 weeks (n = 35 (61.4) 22 (38.6) 
57) 
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Tabl~ 41. Logistic regression-derived Odds Ratio for volume category variable in 221 pulmonary TB 
patients in Kampala, Uganda by first early morning sputum measurement. (Objective 3} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 1.28 
Volume and cavitary 1.601 25% 1 
disease 
Volume and drug 1.466 14.5% 2 
resistance 
Volume and AFB density 1.199 6.8% 3 
at baseline 
Volume and duration of 1.347 5.2% 4 
TB symptoms 
Volume and HIV status 1.3 1.6% 5 
Volume and post- 1.3 1.6% 6 
secondary school 
education 
80 
00 
....., 
Table 42. Multivariable association between unsuccessful pulmonary TB treatment outcome and baseline characteristics in 221 subjects 
with baseline early morning samples. (Objective 3} 
Model 
1 
2 
3 
4 
5 
6 
Factor Level 
!1o~~~· ___ , 
Volume catee:o 
1 Model . _ . Volume category 2: 3 mL 
·caV"ftaiYieSions --- ··present-
at baseline 
AICt Adjusted OR2 
(95% CI)3 
C-
statistic 
Hosmer-
Lemeshow 
test 
~ _ _Q __ __ ------
-- o.6_L ___ ~~()_,Q~-- ~~-
1.60 (0.67 -3.82) 
i72"(L"o7-~6.93f~·-
Hosmer- Model 
Lemeshow p-value 
p-value 
fJ.L~---- _____ ~:1-L __ _ 
Q2Z 
0.29 O.o4 __ _ 
Model 139.1 0.71 2.23 0.69 0.006 
% Change Decision 
in 
Adjusted 
OR 
32%---~~~K:ee}:iTn ­
model 
..Y91!!..Il1_e cate_g9.i:Y _ ~~-~1- - - --==: ._:·--------~•!]7lQ,71-1.38l_ ~:=~==-~~=:=-·-·" - ~-=--- ___________ 9.:.?:C:~~ 
Cavitary lesions present 2.51 (0 .96-6.53) 0.06 
at baseline 
Drug resistance --- --- - --- - -·---- 3.6 ·i"(l.34=9.~------~--R.esistanr w 1 .. 
or 2nd line ae:ent 
Model 133.4 0.73 
__ Volume cateifu_ry 2:· 3 mL _- -- ~,v .... _ 
Cavitary lesions present 
at baseline 
Drug resistance Resistanfto 1st 2.86 (1.04-7.84) 
~~ 
2.2 (1.1-4.40) 
1 .Lor ~line age~nc:.:t,___~ 
Baseline sputum Increments of 
bacillary grade 1 + 
0.01 
5.39 0.72 
~
0.24 
0.04 
7.9% 0.03 Remove 
from 
model 
I Model . . 136.7 0.71 2.81, 0.83 _ 0.002 ~~I 
Volume category 2: 3 mL 1.94 (0 ~ 77-4.89) 0.16 
~Cavitary lesions--present - -----·2:4[o:9~-6.36}"~ - --,--0.08 
at baseline 
Drug resistance Resistant to 1st 
or znd line agent 
Duratio--n~o-f=-T"""'B-~-2:'""1""2-weeks --· 
symptoms 
Model 138.3 
3.14 (1.12-8.77) 
1.03 (1-1.08) 
0.03 
0.04 
0.76 0.82 0.98 0.02 
9.6% Remove 
from 
model 
00 
N 
Y2ill.!nllatego_ry ___ ;:::l__l!l~- · ·=· ~J·~.~. 
Cavitary lesions present 
at baseline 
Drug resistance Resistant to 1st 
1·~1(9:7.:~ :.1~ 1 .. 
2.71 (0.96-7.61) 
1~ . . or 2nd lin~~K~_! ____ _ HIV status Infected 
3.1 (1 .12-8.) 
1.23 (0.51-2.98) 
Final Model~ - --· -. -· 135.7 __ _ . ~_0.7L _ 
1.95 (0.77-4.97) 
2:23(0:84-5:97)' 
Resistant to 1•t 4.01(1.44-11.1) 
Post~secondary 
school education 
1AIC =Aka ike's Information Criterion 
20R = Odds Ratio 
395% Cl = 95% Confidence Interval 
3.66 (1.22-11) 
0.20 
0.06 
0.03 
0.65 2.3% Remove 
0.16 
0.11 
~ .... ··------·-··-·------oJJ-68~-~~ 
0.02 
from 
model 
10.2% Kee p in 
--~del 
Table 43. Bivariate analysis between pulmonary TB treatment outcome (by sputum culture) and baseline 
characteristics in 91 HIV-seropositive patients in Kampala, Uganda by first spot sputum measurement. 
{Objective 3} 
Characteristic Level Successful Unsuccessful Odds Ratio p value 
outcome (n= outcome (n= (95%CI} 
69} 22} 
Gender Female (n = 41) 34 (82.9) 7 (17.1) 1.94 (0.7-5.4) 
M~IE! (n= ~-~1 ??J?1.4) 
.................. 
14 (28.~) . 
Age group <30 (n = 17) 12 (70.6) 5 (29.4) 1.35 (0.29-6.26) 1 
30-40 (n =56) 44 (78.6) 12 (21.4) 0.89 (0.24-3.22) 1 1 
>40 (n = 17) 1?.J?.Ei.5) 4 (23 .?}_ 1 
Retreatment TB · No(~-;;, 27) 20 (74) 7 (26) 0.82 (0.29- 0.79 
_yes (r1 :: 63) . ~~J77 . ~.L .. 14 (22.2) 2.320 
Drug Resistance No resistance (n = 62 (79.5) 16 (20.5) 2.78 (0.78-9.88) 0.14 
78) 
Resistan~~ (n = 12) 7 (58.3) 5 (41.7) 
Smoke history Never smoked (n = 44 (80) 11 (20) 1.6 (0.6-4.29) 0.44 
55) 
Ever smoked (n = 25 (71.4) 10 (28.6) 
35) 
Volume category <3mL(n=76) 62 (81.6) 14 (18.4) 4.43 (1.34- 0.02 
.... ~. 3 f11L(r1 _::l~J. 
-
. JJSO) 7 (SO) 
····-
14.67) 
Cavitary lesions Absent (n = 42) 37 (88.1) 5 (11.9) 3.96 (1.29- 0.02 
at baseline Present (n = 43) 28 (65.1) 15 (~4.9) 12.21) 
Days to sputum s; 6 days (n = 37) 27 (73) 10 (27) 0.7 (0.26-1.89) 0.61 
positivity - > 6 days (n =53) 42 (79.2) 11 (20.8) 
culture 
·---
AFB density at 0 (n = 8) 5 (62.5) 3 {37.5) 1.56 (0.31-7.78) 0.68 
baseline 
1+(n=8) 6 (75) 2 (25} 0.87 (0.15-5.03} 1 
2+(n=15) 13 (86.7) 2 (13.3) 0.4 (0.08-2.1} 0.47 
3+ (n = 23) 19 (82.6) 4 (17.4) 0.55 (0.15-2.01) 0.53 
26 (72.2) 1 4+ (n_= 3~} 1 
.. 
Post-secondary No (77) 63 (81.8) 14 (18.2) 5.25 (1.53- 0.01 
school education 18.05) 
Yes(13) 6 {46.2) . 
.. 
7 {53.8) 
Duration ofTB < 1iweeks(n = 71) 56 (78.9) 15 (21.1) 1.72 {0.56-5.3) 
symptoms ~ 12 weeks (n = 19) 13 (68.4) 6 (31.6) 
83 
Table 44. Logistic regression-derived Odds Ratio for volume category variable in 91 HIV-seropositive 
patients in Kampala, Uganda by first spot sputum measurement. (Objective 3} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 4.43 
Volume and post- 6.366 43 .7% 1 
secondary school 
education 
Volume and cavitary 3.71 16.3% 2 
lesions 
Volume and drug 4.195 5.3% 3 
resistance 
84 
00 
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Table 45. Multivariable association between unsuccessful pulmonary TB treatment outcome and baseline characteristics in 91 HIV-
seropositive subjects with baseline spot samples. (Objective 3) 
Model Factor Level AICl Adjusted OR2 (95% C-statistic Hosmer- Hosmer- Model %Change in Decision 
CI)' Lemeshow Lemeshow p-value Adjusted OR 
test -value 
1 I _M_odeL~~-~ _ ~-- g __ - - - ---- --- T1l~--~ .. - __ ,~g,o ~ .. - -~---··---·------·-------· 
<>:3 mL 4.43 (1.34-14.67 
2 I M_p_c!_~l_-~~--- -~-~-----~_9d_ ______ - ________ 0..:?_2~--_Q~008 -~ 
Volume category ... <>: 3 mL -~-- _, ....§}LC!·~;:,~~-}l Post:s ecoli.Cfax-Y - -.. ·· -Yesw-~ ~-~ 7.45 (1.99-27.93) 
school education 
3 I Model 83 0.75 5.28 
vofUine 2a"tegQ!i 
Post-secondary Yes 
school education 
Cavitary lesionsat . v-presenr - --· --- --3~49. (1~05:11.64) 0.04 17.7% Keep in 
baseline model 
4 1 Model 84.4 0.76 7.59 0.18 0.001 
Volume category <>:3mL 5.23 (1.26-21.62) 0.02 
Post-secondary Yes 6.79 (1.7-27.131 0.006 
school education 
Cavitary lesions at present 3.45 (1.03-11.64) 0.05 
baseline 
Days to sputum > 6 days 1.87 (0.43-8.26) 0.41 0.2% Remove 
culture positivity from 
model 
Final I Model 83 0.75 
-
5.28 0.15 0.0005 
Volume category ... <>: 3mL 5.24 (1.27-21.58) 0.02 
"PO-st-Secondary ----- ¥eS -6:s4-·cr7z-~z7 ."23J-------~----------~-----··-----~ 0.006 
school education 
-------
Cavitary lesions at present 3.49 (1.05-11.64) 0.04 
baseline 
1AIC =Aka ike's Information Criterion 
20R = Odds Ratio 
395% Cl = 95% Confidence Interval 
Table 46. Bivariate association between pulmonary TB treatment outcome (by sputum culture) in 105 
HIV-seronegative patients in Kampala, Uganda by first spot sputum measurement. {Objective 3} 
Characteristic Level Successful Unsuccessful Odds Ratio p 
outcome outcome (n= (95%CI) value 
(n= 76) 29) 
Gender Female (n = 23) 17 (73.9) 16 {69.6) 0.87 (0.31-2.5) 1 
Male(n=.= 8Q) 57 (?1.~} 2~_ (28.~L . 
Age group <30 (n =53) 44 (83) 9 (17) 0.21 (0.07-0.62) 0.008 
30-40 (n = 28) 19 (67.9) 9 (32.1) 0.47 (0.15-1.5) 0.25 1 
>40(n =}2) __ 11 (SO) 
.. 1! (SO) 1 
.. 
Retreatment TB No (n = 16) 13 (81.3) 3 (18.7) 1.85 (0.49-7.03) 0.55 
Yes (n = 87) 61 (?0.1) 26 (29.9) .... 
Drug Resistance No resistance (n = 81) 65 (80.2) 16 (19.8) 5.87 (2.14-16.12) 0.0008 
Resistance (n = 22) 9() 3() 
.... . ·. 
Smoke history Never smoked Tn ;;, so (78.1) 14 (21.9) 2.23 (0.93-5.36) 0.11 
64) 
.. ,,, 
Eyer.~ITlok~d.(n = ~~.L ~~- (61.?) 1?. (3.8:?L 
Volume category < 3 ml (n = 76) 55 (72.4) 21 (27.6) 1.1 (0.42-2.9) 1 
:::: 3 ml (n =_27) 19 (70.4) 8 (29.6) 
Cavitary lesions Absent {n = 18) 14 (77.8) '4 (22.2) 1.4 {0.44-5) 0.77 
at baseline 
..... Present _{n _= 84) .. 59 (70.?) 
.. . 25 l29.8J .... 
AFB density at 0 (n = 3) 3 (100) 0 (0) N/A 0.56 
baseline 
1+ (n = 7) 7 (100) 0(0) N/A 0.18 
2+ (n = 7) 4 (57.1) 3 (42.9) 1.94 (0.39-9.6) 0.41 
3+ (n = 25) 16 (64) 9 (36) 1.46 (0 .54-3.92) 0.45 
4?- {n=61) 44 (72.1) 
..... ~7 ( ~_7 .9) 1 
_,, .... 
1 
Days to sputum :s; 6 days (n = 42) 25 (59.5) 17 (40.5) 0.36 (0.15-0.87) 0.03 
positivity - > 6 days {n = 61) 
culture 49 j_8q.3) 12 (19.7) 
-
Post-secondary No (91) 68 (74.7) 23 (25.3) 3 {0.87-10.08) 0.09 
school education Yes(~2) _ .. 6_(50) 6 (50) 
Duration of TB < 12 weeks (n = 66) 51 (77.3) 15 (22.7) 2.07 (0.86-4.99) 012 
symptoms :::: 12 weeks (n = 37) 23 (62.2) 14 (37.8) 
86 
Table 47. Logistic regression-derived Odds Ratio for volume category variable in 105 HIV-seronegative 
patients in Kampala, Uganda by first spot sputum measurement. (Objective 3} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 1.103 
Volume and drug 1.219 10.5% 1 
resistance 
Volume and age group 0.997 9.6% 2 
category 
Volume and baseline 1.172 6.3% 3 
days to sputum culture 
positivity 
Volume and duration of 1.14 3.6% 4 
TB symptoms 
Volume and smoking 1.07 2.7% 5 
history 
Volume and post- 1.116 1.2% 6 
secondary education 
87 
00 
00 
Table 48. Multivariable association between unsuccessful pulmonary TB treatment outcome and baseline characteristics in 105 HIV-
seronegative subjects with baseline spot samples. (Objective 3} 
Model Factor Level AIC1 Adjusted QRZ 
(95% Cl}3 
C-statistic Hosmer-
Lemeshow 
Hosmer-
Lemeshow 
I 
Model 
p-value 
% Change in 
Adjusted OR 
Decision 
...... ~ ... 
"""- -
1 
_M_9del , __ , -·-··--·---~----~~~ 
.! 26.4 -----rico-:-42~2 . 9y-~! --~-~-.-Q ___ .~____ N.:/!L_~-~~}1~~---- ~------------··"· -------·----- ---Volume category ~3 mL 
2 Model 116.1 0.68 0.007 0.93 0.002 
--···-·· .. · ·-·---·-·· "' "·~-~-~---"'"···· -------··-··,0·~----------- ......_. _  ...__ ····-···-·"----·--··---~·--···-·-- -"" . .....:. ............. ~ -- ---------•"'-"'"' __ _.,_ ____________ .......,....._ ___ ... ___ + -•···· ·-""·"'""' ..... ··· ·- ····--·'""'·-·"''"'- ~--.-.~~'"'"-····-""'---------- .. ~-·--··"""''-'''' ~....... -"'··--- - - ·-""-·· -~----··:,,;,,.,_ ............ ___ ..._ .... - - ~~ ........ _ .. _____ ,., ... 
Volume category ~3 mL 1.22 (0.43- 0.71 
'Drug resiSta-nce 
3.44) 
" Re sistant'to ~t' -·~~, .. ----""5.94 (2:is-:. ·· ---- -·· -------~~---.. --·· ~-·- ·· -· ··--- -~---~-~--- o:oo6'6 ·- 10.9% - .... ;< ·-···- Ke~pln -~ ..... 
or 2nd fine agent 16.38) model 
3 Model 110.3 0.78 5.57 0.35 0.0002 
' vofU'riie"Catei;;;:y- ~ 3l nL ~-·--- --'"'--· T h co:38- ~--..,. ..... ~-. ___ .. ,, ____ ~ ---:- ,, _________ ... 0.83 ·----- -~--~-~~-~~·--,.--~-,.~---
_.......-.z.;.."" -~ = ----~---~-~------C~~--~·3U~·~- -~-~---~----~-- ·•------~-~~---~--·-~-------·~---···--·-----·~· ---·----~----
Drug resistance Resistant to 1st 6.22 (2.12- 0.0001 
-Age group 
or 2nd line agent 18.24) 
--.- >46'·--~- ""'"'--.--~'~if(i.26-- ------·- .. ---""'---~-.,~,----·-~-----~-- o.o o6~-.-s:z% -·~-'Remove .. _, ··· 
4.12) from model 
4 Model 116.2 0.71 0.20 0.98 0.003 
Volume category ~3mL 1.23 (0.43- 0.7 
3.55) 
Drug resistance Resistant to l •t 4.87 (1.7-14) 0.003 
or 2nd line agent 
Baseline days to >6 days 0.51 (0.2- 0.16 0.8% Remove 
culture positivity 1.32) from model 
5 Model . 115.8 0.70 1.68 0.79 0.002 
Volume category ~3mL 1.26 (0.44- 0.67 
3.59) 
Drug resistance Resistant to 1st 5.97 (2.13- 0.0007 
or 2nd line agent 16.75) 
Duration of TB ;::: 12 weeks 2.1 (0.82- 0.12 3.3% Remove 
symptoms at 5.41) from model 
baseline 
6 Model 112.3 0.76 0.57 0.97 0.0004 
Volume category ~ 3 mL 1.17 (0.4- 0.77 
3.44) 
Drug resistance Resistant to 1st - ? .06_(2.05- 0.0002 
- - - -
or 2nd line agent 
Smoke history Ever smoked 
7 Model 116.1 
24.57) 
3.35 (1.22-
9.23) 
0.02 
0.87 0.83 0.002 
4.1 o/o Remove 
from model 
-·Vo lumecategory_ .... ;:: 3 mL 
0.68 
1.23 (0:43· ·~-~----- _ .. _. __ ------.. - ----- "0:7 ---~. ~~--·~·~·-~-.. 
---.. --·------ •"'-
0.0009 
3.51)~ o•· , .,.~---
5.72 (2.05-6) 1- ----Drug resistance Resistant to 1st 
0.8% U.l!:l 
I . or 2nd line agent 
Post-secondary Yes -.-.o-. 4':06 (1.08-~~~ m m • - ""="' 
school education 15.3U_ 
Final I Model 110.3 0.6~8~- 0.007 0.93 0.0002 
0.83 voJUme category ;:: 3 mL -- -1~12-(0:38-
~~~-~-~~· ~~~---· . ---.li1L .. ~-·--~ __ ... ___ . ---· -----·---·. ··-..... ""-"""""'""-·-~ ............. ----'-"""-----------··----
Drug resistance Resistant to 1st 6.22 (2.12-
or 2nd line agent 1_8.24) 
1AIC =Aka ike's Information Criterion 
20R = Odds Ratio 
~ 395% Cl = 95% Confidence Interval 
0.0001 
....... , 
Remove 
from model 
-~.~--
Table 49. Bivariate association between pulmonary TB treatment outcome (by sputum culture) and 
baseline characteristics in 103 HIV-seropositive patients in Kampala, Uganda by first early morning 
sputum measurement. (Objective 3} 
Characteristic 
Gender 
Age group 
Retreatment TB 
Drug Resistance 
Smoke history 
Volume category 
-· 
Cavitary lesions 
at baseline 
AFB density at 
baseline 
Days to sputum 
positivity -
culture 
--···· 
Duration of TB 
symptoms 
••·•v• ,. ., •.. , 
Post-secondary 
school education 
Level Successful 
outcome (n=82} 
Female (n = 49) 
.. Male (!"'=.??) 
<30 (n = 21) 
30-40 (n = 60) 
>40 (n ~ 21.) 
No (n = 24) 
Yes (n =?.?L 
No resistance (n 
= 91) 
Resistance (n = 
12) . 
Never smoked 
(n = 66) 
Ever smoked (n 
= 36) 
42 (85.7) 
39 .. (7?.6) . 
17 (81) 
49 (81.7) 
15 (71.4) 
17 (70.8) 
64 {8?:1) 
75 (82.4) 
7 (58.3) 
53 (80.3) 
28 (77.8) 
< 3 ml (n = 74) 63 {85.1) 
. } 3 mL(!l = 2~)_ .. .1.~ {6?5). 
Absent (n = 44) 40 {90.9) 
. Pre:;ent_(n = 4_9} ·- ~4 (69 :~) 
0 (n = 5) 5 {100) 
1+(n=7) 6 (85.7) 
2+ (n =12) 11 {91.7) 
3+ (n = 12) 10 {83.3) 
4+ (n = 66) -- ~9 (7~: 2) 
~6 d~ys ·(~;, 41) 30 {73.2) 
> 6 days (n = 61) 
-· . ~ .. .... 
< 12 weeks (n = 
84) 
;:, 12 weeks (n = 
~9) .... 
No (89) 
Yes (13) 
.?1 (83.6) 
69 (82 .1) 
13 (68.4) 
74 (83.1) 
7 (53.8) 
90 
Unsuccessful 
outcome (n= 21) 
7 (14.3) 
1_'t(?6.~J. .. 
4 {19) 
11 (18.3) 
6 (28.6) 
7 (29.2) 
_  14 (17.9) 
16 (17.6) 
5 (41.7) 
Odds Ratio 
(95%CI) 
2.15 (0.79-
?:?9) .... 
0.59 (0.14-2.49) 
0.59 (0 .18-1.77) 
1 
0.53 {0.19-
1:~ 2) ___ _ 
3.35 (0.94-
11.9) 
-·-----~ ···"~----..... 13 (19.7) 1.17 (0.43-
8 (22.2) 
11 (14.9) 
~OJ?4..· ?L. 
4 (9.1) 
15 (30._6)_ 
0 {0) 
1 (14.3) 
1 (8.3) 
2 {16.7) 
l?J~S:~) .. 
11 (26.8) 
19 (16.4) 
15 (17.9) 
6 (31.6) 
15 (16.9) 
6 (46.2) 
3.14) 
3.01 {1.11-
8.18) 
4.41 (1.34-
14.56) 
... N/A 
0.48 (0.05-4.28) 
0.26 (0.03-2.18) 
O.S8 (0.11·2.9) 
1 
0.53 (0.2-
1.41) 
2.12 (0.69-
6.49) 
4.23 (1.24-
14.37) 
p value 
0.15 
0.72 
0.36 
1 
0.26 
0.07 
0.80 
0.03 
0.01 
0.33 
0.67 
0.28 
0.72 
1 
0.21 
0.02 
Table 50. Logistic regression-derived Odds Ratio for volume category variable in 103 HIV-seropositive 
patients in Kampala, Uganda by first early morning sputum measurement. {Objective 3} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 2.447 
Volume and cavitary 2.914 19.1% 1 
lesions at baseline 
Volume and drug 2.859 16.8% 2 
resistance 
Volume and post- 2.496 2% 3 
secondary education 
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Table 51. Multivariable association between unsuccessful pulmonary TB treatment outcome and baseline characteristics in 103 HIV seropositive 
subjects with baseline early morning samples. (Objective 3) 
Model Factor Level AJCl Adjusted QRZ C-statistic Hosmer- Hosmer- Model %Change Decision 
(95% CI)3 Lemeshow Lemeshow p- p-value in Adjusted 
~~------------------~~--------------~~------~te_s_t ________ _.v.al~e OR 
1 I _Model ______ ;__,_" ___ ~-~-10.1-..:.!L._~- .0.60 
Volume ~ 3 mL 2.45 (0.9-
category 6.69 
2 I .M2c:!f:!l __ ~- ---····--------··-~--··· · ··---~··- -·1!2,?_. _ ___ __ __ , _~----·-· -·-~---- ~----~-- ():Z~ ..... . 
Volume ~ 3 mL 2.91 (0.95-
~g2__ry -------·--~ 8.98)_ ~ 
Cavitary lesions Yes 4.47 (1.32- 0.02 18.8% Keep in 
I at baseline 15.07) model 3 Model 90.2 0.73 2.07 0.56 0.008 
Vo lume ~ 3 mi~ -·-~ '~ ~3Jf9(0.9s:- - ·-- -~ ---- -- ~-~~.- -p --- 0 .0 5S 
~ateg~-----~---···--···········'-""· · ·· · ··· ·· - ---~ -----·-·· · -~---~~?.~1 .... ~--- ····----·-····"·-~---- - · 
Cavitary lesions present 4.24 (1.25- 0.02 
\.0 I at baseline 14.38) 
N ~r, :::-::::-~=~0-Resistantto' ~'2:6[o:59- 0.2 6.2% Remove 
1st or 2nd line 11.4 7) from 
I r ~ 4 Model 87.4 0.90 2.7 0.61 0.002 
~mL -~--"-2.86(0.89- _...... --- -- 0.68 
- ~~---=-9=.2)~ -·-··--~-- ------~- .. _... ~- -~=-
present 4.38 (1.26- 0.02 
15.21) Yes-- --- - 4.32 (1.12- 0.03 1.7% Remove 
16.74) from 
model 
Final I Volume ~ 3 mL 2.91 (0.95- 0.72 0.12 0.94 0.06 
category 8.98) 
c.ivitarylesioils - Yes 4.47 (1.32- o:oz 
at baseline _ 15.01 
1AIC =Aka ike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
Table 52. Bivariate analysis between pulmonary TB treatment outcome (by sputum culture) and baseline 
characteristics in 117 H IV-seronegative patients in Kampala, Uganda by first early morning sputum 
measurement. {Objective 3) 
Characteristic Level Successful Unsuccessful Odds Ratio p value 
outcome outcome (n= 32) (95%CI) 
(n=BS) 
Gender Female (n = 24) 18 (75) 6 (25) 1.16 (0.42-3.26) 1 
r-Aai~Jn:= ~3) .. 6?(7?) 26(28) 
Age group <30 (n =59) 47 (79.7) 12 (20.3) 0.38 (0 .14-1.06) 0.1 
30-40 (n = 25) 15 (60) 10 {40) 1.53 (0.51-4.57) 0.58 
>40 (I')= 33) ~? {69.7) 10 {30.3) 1 1 
Retreatment TB No (n = 17) 13 (76.5) 4 (23.5) 1.26 {0.38-4.21) 
Ye~ (n ::: ~0()) 7 2.(?2) 28(?8) -- --
Drug Resistance No resistance (n 75 (81.5) 17 (18.5) 6.62 (2.54- <.0001 
= 92) 17.25) 
Resistance (n = 10 (40) 15 (60) 
2S) 
··--· 
... .. 
·-· 
. Smoke history Never smoked (n 55 (79.7) 14 (20.3) 2.36 (1.03-5.4) 0.06 
= 69) 
Ever smoked (n = 30 (62.5) 18 {37.5) 
~8) 
Volume category <3ml(n=80) 56 (70) 24 {30) 0.68 (0.27-1.7) 0.38 
__ ?. 3 rT1L(n:= ~.?L . 29 p8.4) ~P~:6l. 
Cavitary lesions at Absent (n = 18) 14 (77.8) 4 (22.2) 1.44 {0.44-4.76) 0.78 
baseline 
__ .Prese':l.t (n = .. ~6)_ ..... 68,_(7Q.8) ...... ?~ (2~: 2) 
Days to sputum s; 6 days (n = 79) 63 (79.7) 16 {20.3) 2.86 (1.23-6.67) 0.02 
po~itht~ty- culture > 6 days (n = 38) 22 (57.9) 
... 
16 {42.1) 
AFB density at (j'(i1 = -3) -· -- -- . 3 (100) 0 (O) N/A 0.55 
baseline 
1+{n=3) 3 (100) 0(0) N/A 0.55 
2+ (n = 8) 7 (87.5) 1 (12.5) 0.30 (0.04-2..58) 0.43 
3+ (n = 19) 15 (78.9) 4 {21.1) 0.56 (0.17-L86) 0.42 
4+ (n = 84) 
. .. .. 5?.(67.9) . ?7 .(32.1) 1 •.. .. 1 
Duration of TB < 12 weeks (n = 63 (79.7) 16 (20.3) 2.86 {1.23-6.67) 0.02 
symptoms 79) 
:?: 12 weeks (n = 22 (57.9) 16 (42.1) 
38) 
Post-secondary No (16) 10 (62.5) 6 {37.5) 1.73 (0.57-5.23) 0.37 
school education 
Yes (101) 75 (74.3) 26 (25.7) 
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Table 53. Logistic regression-derived Odds Ratio for volume category variable in 117 HIV-seronegative 
patients in Kampala, Uganda by first early morning sputum measurement. (Objective 3} 
Variables in Model Volume category OR Percent change in Odds Order added to 
Ratio Logistic Regression 
Model in model 
building procedure 
Volume 0.644 
Volume and duration of 0.754 17% 1 
TB symptoms 
Volume and baseline 0.733 13.8% 2 
days to sputum culture 
positivity 
Volume and drug 0.723 12.3% 3 
resistance 
Volume and smoking 0.684 6.2% 4 
history 
94 
1.0 
l.n 
Table 54. Multivariable association between unsuccessful pulmonary TB treatment outcome and baseline characteristics in 117 HIV-seronegative 
subjects with baseline early morning samples. {Objective 3} 
Model 
1 
2 
3 
4 
Factor Level AIC1 Adjusted C- Hosmer- Hosmer- Model 
OR2 (95% statistic Lemeshow Lemeshow p-value 
CI)3 test p-value 
Mod.&__ 
Volume 
catel!ory 
-~----140A ____________ --~- 0.5L ___ ~----.9~-~ ---~rY_~ _ _____ 0.34 
<:3mL 0.64 (0.26-
1.61 
._.M_odel_~~-· - .... _____ . -· ~--137 
Volume ;:: 3 mL 
category 
Duration, __ o~f-=~<:--1~2-w-eeks 
TBsvmotoms 
Model 
Volume <!:3mL 
category 
Duration of 2: 12 weeks 
TBsymptoms 
8ase fiiledays ~ - >6days~--
to sputum 
culture 
136.7 
0.75 (0.29-
1.94) 
2.75 (1.17-
6.58 
0.86 (0.33-
--'2=.26L 
2.67 (1.12-
6.35) 
0.52(0.22~ 
1.22) 
0.65 O.QQ.1 
0.67 1.51 
l_r.f~----~~----1~-~-~·--0_2_!_ ___ 3
<!:3mL 0.93 (0.34-
2.57 
------2:12 weeks 2.52 (0.99-
6.42) 
>6 days o.n co~is-
1.81) 
--~- --~- .. ..... --------- _...,. -~\, ...... ,.-.:. ...... 
Resistant to 5.77 (2.11-
1st or 2nd line 15.78) 
al!ent 
--~- 0.99 _" 
0.82 
0.81 
0.34 
0.02 
0.04 
0.76 
0.03 
0.13 
0.0004 
oli9-
0.052 
0.47 
0.0006 
% Decision 
Change 
in 
Adjusted 
OR 
0.99~-
17.2%·--~ep in 
model 
-14.7% ___ _ 
7.5% 
Keep in 
model 
Remove 
from 
model 
\.0 
0'\ 
5 Model 135.4 0.70 7.43 0.39 0.02 
Volume ~3 mL 0.92 (0.34- 0.88 
category 2.47) 
Duration of <: 12 weeks 2.67 (1.1- 0.03 
TB symptoms 6.46) 
Baseline days >6 days 0.54 (0.22- 0.16 
to sputum 1.29) 
culture 
positivity 
Smoking Present 2.22 (0.94- 0.07 7% Remove 
history 5.27) from 
model 
Final Model 136.7 0.67 1.51 0.82 0.04 
Volume -~;::3mr:~=-~ · · 0.86 (0.33- ...,...---~--···· --··"·--=--~ 0.76 ----__.,..,.----~~-
~'!~gpry__ ---~-~--~--------·-·-·--·-·----2,~§L~--~-.. -- -·------... ·----~--~- ·-· ·---------- . ~ ~---------~-·-~~ ___ ~--·~--------........... ~-~--·· ... --~--.~·-... ..... ... -'... 
Duration of ~ 12 weeks 2.67 (1.12- 0.03 
J:~~~pto~--- ...... ... ~ ~--~~·-·---=--~··§_3 5)_ _______ , ..... ~,~~-~--.. ·- ....... ___ .... ~---~· ............. ~ ... ·~-·-~--·=· --~· .... _ ..... ~. ~- ..... ~·T···-·· ~·~-·--... --~---~- ............. ~---------
Baseline days >6 days 0.52 (0.22-
to sputum 1.22) 
culture 
..J>..Q.~tivi!Y ____ .... --... --....... - - .... ·--- -~ ··- ll < 
1AIC = Akaike's Information Criterion 
20R =Odds Ratio 
395% Cl = 95% Confidence Interval 
0.13 
-~---·---·--~---------~......__._ ___ ...,. ___ __________.... __ __ . __ . ----------- ····------~----~ 
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Figure 1: Boxplots for Volume Distribution 
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Box Plot for Volume Distribution in EM Group 
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Table 1: Demographic, Clinical and Radiographic Features of 391 hospitalized TB patients in Kampala, 
Uganda. 
Characteristic Level Number (range) % 
Age 33 .. ~ (18:::75) 
Gender Male 249 63 .7 
Female 142 36.3 
••• w•o,v 
Sputum volume (mL) 3 .. 3 __ (0.5-2.91 . 
Sputum volume Low(< 3 mL) 203 51.9 
category High (~ 3 rn~l 188 48.1 
HIV status Infected 204 52.3 
Un infected 186 47.7 
Karnofsky score 5 70 67 17.1 
>70 324 82 .9 
..... 
Smoking history Never 259 66.2 
Former 122 31 .2 
Current 10 2.6 
Cavitary lesion Absent 130 38.6 
Present 207 61.4 
-
Drug resistance Absent 359 91.8 
Present 32 8.2 
Retreatment No 109 27.9 
Yes 282 78.1 
. ····--·····-····" 
Duration of TB <12 weeks 60 47.6 
symptoms ~12 weeks 66 52.4 
Table 2: HIV seroprevalence by gender among 391 TB patients in Kamala, Uganda. 
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Table 3: Independent T-test evaluating sputum volume mean by TB t reatment outcome among pulmonary 
TB patients in Kampala, Uganda. 
Sample Cha racte risti c Mean (95% Cl) Standard F-test/p- p-value Error value 
Spot Successful t reatment outcome 4.02 (3 .5-4.55) 0.27 1.28, 0.25 0.06 
Unsuccessful treatment outcome 5.07 (4-6.15) 0.54 
Spot HIV-
Successful t reatment outcome 2.35 (1.76-2.94) 0.29 1.08, 0.97 0.009 infected 
Unsuccessful t reatment outcome 4.05 (2.82-5.28) 0.54 
Spot HIV-
Successf ul t reatment outcome 3.71 (2 .64-4.78) 0.53 1.56, 0.37 0.75 
uninfected 
Unsuccessful treatment outcome 4.03 (2.45-5.61) 0.74 
EM Successful treatment outcome 4.07 (3.41-4.72) 0.33 1.19, 0.64 0.39 
Unsuccessful treatment outcome 4.64 (3 .53-5.75) 0.54 
EM HIV-
infected 
Successfu l treatment outcome 3.43 (2 .83-4.03) 0.29 1.02, 1 0.04 
Unsuccessful treatment outcome 4.99 (2.95-7.03) 0.94 
EM HIV- Successful t reatment outcome 3.64 (2.52-4.77) 0.56 1.65, 0.31 0.71 
uninfected 
Unsuccessful treat ment outcome 4.03 (2.45-5.61) 0.74 
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Table 4. Bivariate analysis of factors associated with pulmonary TB treatment outcome (by sputum 
culture) in 181 TB patients in Kampala, Uganda by first spot sputum measurement. {Objective 3; subjects 
with only one sputum specimen removed) 
Characteristic Level Successful Unsuccessful Odds Ratio p value 
outcome (n=131) outcome (n= 50) (95%CI) 
!Gender Male (n= 130) 83 36 0.67 (0.33-1.37) 
Ferrl .. ~ le { n :=_§§) 48 14 
Age group <30 (n = 66) 51 15 0.18 
30-40 (n = 77) 57 20 
>4~ (n ~. ??) 23 . 15 
---
•.. 
~ HIV status Infected (n = 82) 59 23 0;96 (0.5-1.85) 1 
Uninfected (n = 99) 
72 27 
Retreatment TB No (n =44) 33 11 1.19 (0.55-2.6) 0.7 
... .... _yes (n =:= !3~) 98 39 I ... 
No resistance (~ -~ 116 3.64 (1.63-8.11) Drug Resistance 34 
150) 
Resistance( ~.= 3~)_ 15 16 
""··~- ~··· ·- ·-· ' 
Smoke history Never smoked (n = 85 26 1.71 (0.88-3.3) 0.13 
111) 
Ever smoked (n = 46 24 
70) 
··•·• ......... -······"•¥ •¥ 
-··· 
:volume < 3 ml (n = 137) 105 32 2.27 (1.11-4.67) 0.03 
:category 2! 3 ml (n= 70) 26 18 
Cavitary lesions Absent (n =57) 47 10 2.24 (1.03-4.88) 0.05 
at baseline Present (n = 124) 
40 
AFB density at 0 (n = 15) 4 0.95 
baseline 1+ (n = 12) 10 2 
2+ (n = 20) 15 5 
3+(n=45) 32 13 
4+ _(n = ?9) . 63 26 
-~··· .. 
Post-Secondary No (159) 121 38 3.82 (1.53-9 .54) 0.005 
School 
Education xes. (??l 10 12 
·-
< 12 weeks (n = 128 30 1.98 (0.99-3.95) 0.07 
128) 
2! 12 weeks (n =55) 55 20 
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Table 5. Final multiple logistic regression model for factors associated with unsuccessful pulmonary TB 
treatment outcome in subjects with baseline spot samples (n = 181). {Objective 3; subjects with only one 
sputum specimen removed) 
Model Factor 
Number 
Final Model 
Volume category 
Cavitary lesions at 
baseline 
Post-secondary school 
education 
Duration of TB 
symptoms 
Level 
~ 3 mL 
.......... 
present 
Yes 
~i2week5 
..... ~ ..... -~ ........ ,_ .. _ 
106 
Adjusted Odds Ratio 
(95% CJ) 
p-value 
0.04 
4.89 (1.03-23.2) 0.05 
0.03 (0.0003-0.4) 0.008 
5.42 (1.23-29.84) 0.03 
Table 6. Bivariate analysis of factors associated with pulmonary TB treatment outcome (by sputum 
culture) in 159 TB patients in Kampala, Uganda by first early morning sputum measurement. (Objective 3; 
subjects with only one sputum volume removed) 
Characteristic Level Successful Unsuccessful Odds Ratio p value 
outcome outcome (n= 40) (95%CI) 
(n=119) 
-Gender Male (n= 109) 77 32 0.46 (0.19-1.08) 0.08 
FeJ11al_e (n = ?Ql 42 8 
........ 
Age group <30 (n = 62) 48 14 0.26 
30-40 (n = 64) 50 14 
>40 (n ::.3~) 21 12 
HIV status Infected (n = 69) 55 14 1.53 (0.73-3.24) 0.27 
Uninfec.t~d(n = ?9) 64 25 
.. ... .. .. ..... . ........ ~ •... 
Retreatment No (n = 28) 21 7 1.01 (0.39-2.59) 1 
TB YesJn = 1~!) .. 98 33 
No resistance (n = 134) 107 27 
' Resistance R~sis~ance (':1 = 2?) 12 13 
·-·· 
.. 
Smoke history Never smoked (n = 95) 77 18 2.24 (1.08-4.64) 0.56 
Eve~sr:n oked _(n. = __ 64) 42 22 
. ···-- .. -. 
Volume < 3 ml (n = 106) 81 25 1.28 (0.61-2.7) 0.56 
!category ;::: 3 ml (n = .53) 38 15 
... 
Cavitary lesions Absent (n = 46) 40 6 2.87 (1.11-7.4) 0.03 
at baseline Present (n = 113) 79 34 
0 (n ·= 7), - -···· ••v• .. AFB density at 7 0 0.04 
I baseline 1+ (n = 6) 6 0 
2+ (n = 13) 12 1 I 
! 3+ (n = 25) 21 4 
I - .. 4+(':1 =. 1<?8) 73 35 ..... 
Post-Secondary No (136) 106 30 2.72 {1.09-6.81) 0.04 
School 
Education Yes (23) 13 10 
1 Duration ofTB < 12 weeks (n ;ll5) ·-·· 93 22 2.93 (1.37-6.26) 0.007 
! 
!symptoms ;::: 12 weeks (n = 44) 26 18 
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Table 7. Final multiple logistic regression model for factors associated with unsuccessful pulmonary TB 
treatment outcome in subjects with baseline early morning samples (n = 159). (Objective 3; subjects with 
only one sputum specimen removed) 
Model Factor Level Adjusted Odds Ratio p-value 
Number (95 % Cl) 
Final Model 0.006 
.......... 
~ 3 mL 2.57 (0 .9-7.32) . 0.08 
present 0.15 
present 3.17 (0 .93-10.8) 0.07 
Yes ·· ········· · ······ o :2i(o.06~o :7s) 0.02 
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